List of Antibodies Companies in California - 284

3T is an immunotherapy company developing next-generation, transformative therapies for the treatment of solid tumors and other immune-mediated diseases in broad patient populations. By leveraging the power of the immune system to recognize, target, and destroy cancer cells, 3T's technology is advancing the development of next-generation therapies that have the potential to be safer, more effective, and even curative for difficult-to-treat cancers.

4DMT is a clinical stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market and rare diseases. Our vector discovery platform Therapeutic Vector Evolution harnesses the power of directed evolution, a Nobel Prize-winning technology, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors with improved therapeutic profiles compared to wild-type vectors. Our product design, development and manufacturing engine empowers us to efficiently create our valuable and diverse product pipeline. This combination of bold innovation and relentless execution gives 4DMT the capability to revolutionize genetic medicines and to strive for potential curative therapies. We have built a deep portfolio of genetic medicine product candidates, with five product candidates in clinical trials for seven patient populations. We are taking genetic medicine to new heights and into new disease areas to overcome challenges not addressed by existing medicines. This incredible challenge drives our relentless and talented team. Our people are the essence of our inspiring, innovative and collaborative environment that encourages individual contributions and provides opportunities for career development. We seek the best in the industry who identify with our mission and our bold and innovative results-driven approach. Our 4 Guiding Principles drive the way we work together: - Dare to Cure - Break Boundaries - Beyond Yourself - Prepare & Execute Relentlessly Join us in creating the future of genetic medicine.

Aarvik Therapeutics is pursuing exciting, novel molecules with an improved therapeutic index for several oncology targets by combining a novel modular antibody platform with multiple target mechanisms.

AAT Bioquest®, Inc. (formerly ABD Bioquest, Inc.) develops, manufactures and markets bioanalytical research reagents and kits to life sciences research, diagnostic R&D and drug discovery. We specialize in photometric detections including absorption (color), fluorescence and luminescence technologies. The Company's superior products enable life science researchers to better understand biochemistry, immunology, cell biology and molecular biology. AAT Bioquest offers a rapidly expanding list of enabling products. Besides the standard catalog products, we also offer custom services to meet the distinct needs of each customer. Our current services include custom synthesis of biological detection probes, custom development of biochemical, cell-based and diagnostic assays and custom high throughput screening of drug discovery targets. AAT Bioquest® is committed to constantly meet or exceed its customer’s requirements by providing consistently high quality products and services, and by encouraging continuous improvements in its long-term and daily operations. While we continue to rapidly expand, our core value remains the same: Innovation and Customer Satisfaction. We are committed to being the leading provider of novel biological detection solutions. We promise to extend these values to our customers during the course of our service and to continue to support our customers with new products and services.

The remarkable specificity and safety of antibody drugs have been limited to blocking inactivators for the largest class of drug targets. Abalone Bio develops antibody drugs that activate, enabling us to turn on previously inaccessible biological activities like anti-cancer or anti-inflammatory actions.

As researchers are focusing their efforts on determining the biological functions, interactions and regulation of the human proteome, Abbiotec is dedicated to developing cell biology-based research tools that assist scientific discoveries. Besides custom services, Abbiotec offers over 12,000 antibodies, proteins, peptides, lysates and kits to assist researchers in understanding human biology and diseases at the cellular and molecular levels.

AbboMax is a biotechnology company that offers high quality, diagnostic-grade products and professional custom services for research purposes.

Abcentra develops oxidized LDL blocking therapeutics to treat cardiovascular inflammation. Many patients worldwide live with substantial risk of a major cardiovascular event because of chronic inflammation. This includes patients who have recently had a heart attack, and patients with calcific aortic valve disease. It also includes patients with chronic inflammatory diseases such as psoriasis, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE). Abcentra is developing a potential solution for patients with cardiovascular inflammation – therapeutics that target oxidized low-density lipoprotein (LDL). Oxidized LDL is a well-described pro-inflammatory mediator that is strongly implicated in atherosclerotic cardiovascular disease, type 2 diabetes, calcific aortic valve disease and several inflammatory diseases. Oxidized LDL blockade offers a promising new way to treat cardiovascular inflammation and meet large unmet medical needs in cardiovascular disease. Our pipeline focuses on developing oxLDL-blocking therapeutics for patients who have significant residual risk of major a cardiovascular event from chronic inflammation (see Pipeline). Our lead candidate, orticumab, is a fully-human, first-in-class antibody that targets a specific oxidized LDL epitope. Orticumab is currently in phase 2 in psoriasis patients with cardiometabolic risk factors. Several additional indications are also being pursued. Abcentra has offices in Los Angeles. The Company’s ownership includes world-renowned Los Angeles hospital, Cedar-Sinai. Our team includes experienced drug developers and founding scientists that pioneered our approach to oxidized LDL blockade.

Abeomics Inc. is founded by scientists for the scientists. Our immunologists, cell biologists and business professionals have contributed for over 25 years to the growth and success of global companies including BD Biosciences, eBioscience and IMGENEX Corporation. We bring our experiences to develop well-validated and specific antibodies by traditional hybridoma technology and by genetic engineering to produce recombinant mouse and rabbit monoclonal antibodies.

Abcepta is a biotechnology company that specializes in developing primary antibodies and custom services for research and drug discovery.

Abilita Therapeutics is a biotechnology company focused on redefining the druggable landscape for multi-span membrane proteins, including G Protein Coupled Receptors (GPCRs), transporters and ion channels. We are building a rich pipeline of high-value assets for such targets, with the goal of becoming the leader in discovering and developing first- and best-in-class antibody therapeutics.

Ablexis offers the AlivaMab® Mouse platform, a suite of transgenic mouse strains for human therapeutic antibody discovery. AlivaMab Mouse strains are uniquely designed to be better for human therapeutic antibody discovery and development, for applications across antibody drug discovery including highest quality IgGs, singe-domain VH, multispecifics, ADCs, CARs, TCRm, and other modalities. The AlivaMab Mouse strains are well-documented for generating drug-like antibodies with broad combinatorial and somatic diversities, high affinities, specificity, and excellent developability properties. Users of AlivaMab Mouse include the world’s largest pharmas, public and private biotechs, and leading academic institutions. AlivaMab Mouse-derived antibodies in clinical development span formats including IgG, multispecific, ADC, and CAR. Many partners use AlivaMab Mouse at Ablexis’ sister company, AlivaMab Biologics, a leading provider of services in antibody drug discovery, engineering, and protein sciences. Visit us at www.ablexis.com to learn more. For inquiries about licensing the AlivaMab Mouse, contact us at info@ablexis.com.

Ab Studio Inc. is a biotech company in the San Francisco Bay Area. We have extensive knowledge and expertise in the discovery, optimization, and development of therapeutic antibodies with complex designs, and combine conventional approaches with computer-aided antibody design in this process. Ab Studio believes in 'Quality by design' and aims to address current limitations in the field of therapeutic antibodies with novel technology platforms including multi-specific and internalization antibodies. Please visit our website for more details and partnership/service opportunities http://www.antibodystudio.com

Abterra Biosciences is reimagining antibody discovery and sequencing by harnessing the latest next-generation sequencing, mass spec, machine learning. Abterra Biosciences is enabling the next-generation of antibody therapeutics. Our technologies use the latest in next-generation sequencing.

AbTherx is advancing medicine with revolutionary technologies that accelerate and enable therapeutic antibody discovery. Through an exclusive partnership with Gilead Sciences, AbTherx has released Atlas™ Mice, a suite of novel transgenic technologies designed for unmatched performance and FTO. For over 20 years, AbTherx’s passionate, innovative, and collaborative team has pushed the boundaries of antibody discovery technologies, leading to over 1,000 successful antibody discovery campaigns and 13 marketed therapeutics. AbTherx’s industry-leading team creates transformative solutions to overcome the most demanding challenges in delivering innovative medicines. Committed to making its technologies accessible to all, AbTherx offers flexible partnering models that meet the needs of drug developers of all sizes.

The company providesmolecular biology services includingproduction of antibodies, GPCRs, kinases, nuclear receptors, and many other classes of drug targets and therapeutic proteins

ACELYRIN, INC. (Nasdaq: SLRN) is a Los Angeles area-based late-stage clinical biopharma company – with additional operations in the San Francisco Bay area – focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising product candidates. ACELYRIN is embedding a corporate culture of Courageous Caring™ -- placing patients first and embracing the concept that all of us are better than any one of us -- as we seek to addresses the most basic human needs: to live a productive life free from diseases.

Acepodia is a clinical-stage biotechnology company developing innovative and highly effective cell therapies for cancer that are broadly accessible for patients. Leveraging its Antibody-Cell Conjugation (ACC) technology, the company links tumor-targeting antibodies to its proprietary immune effector cells, such as gamma delta T cells and natural killer (NK) cells to create novel antibody cell effector (ACE) therapies, which have increased binding strength against tumors that express low levels of tumor antigens. Acepodia is made up of seasoned leadership and scientific experts dedicated to advancing its robust pipeline of off-the-shelf ACE therapies with the potential to bring powerful, accessible cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers.

Adcentrx Therapeutics is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease fighting power of small molecule payloads, Adcentrx strives to develop next generation targeted therapies for improving patient treatment options.

AdvanBio Inc., www.Advabio.com, a subsidiary of Autobio Diagnostics in the U.S is a fast-growing biotechnological company based in Irvine, CA. Established in 2021. We specialize in providing cutting-edge IVD Quality Control products & Reagents designed for a diverse range of analytes. In addition, we are committed to providing global partners with high-performance IVD Critical Raw Materials and services such as: • FDA Submission • Assay Development • Product Sales • New Technology/Biomarker Development We are committed to the advancement of medical laboratory technology and dedicated to the promotion of human health. We empower medical providers in making pivotal biomarker & diagnostic decisions with our portfolio of innovative technologies. #Advanbio#ADLM

Aegis Life, Inc. is a biotechnology company founded in early 2020 with a mission to prevent and treat existing, emerging, and future contagions. Our nucleic acid delivery technology Fusogenix PLV stems from more than a decade of research and development in gene delivery. We actively leverage the Fusogenix PLV platform to accelerate the discovery, clinical development, and manufacture of vaccines and therapeutics for infectious diseases.

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. The NULISAseq Inflammation Panel contains 200+ important markers related to immune and inflammatory diseases and will run on our ARGO™ System. This innovative platform allows for a fully automated workflow with less than 30 minutes hands on time from sample to data.

Alcala Labs was founded by a partnership between a healthcare attorney specializing in the defense of individual and institutional healthcare providers and a physician with one of the largest pain management practices in Southern California. The lab grew out of frustration with existing laboratory providers and the conviction that Alcala Labs could do better. Smaller labs were not scientifically up to the task and, in many cases, were simply dishonest about the services they provided. Larger labs were either unresponsive or subcontracted critical complex lab services to unaccountable third-party labs . Alcala Labs was built to react quickly to the needs of physicians who need to understand drug use and efficacy in their practices. The Alcala difference is accessibility to its physician customers, responsiveness to their needs and inquiries, and customizable lab testing. If a physician has a medical-legal question that arises from testing, he can immediately reach the company's healthcare attorney President. If a physician requires insight into how a particular test affects the course of a patient's care, she can engage in a dialogue directly with the lab's Medical Director. If there are questions about science and the development of new tests, our highly credentialed scientific team can be reached directly. Widely in demand among a variety of specialties, Alcala Labs is of especial importance to drug rehabilitation, pain management, and psychiatry practices. We're able to add assays as illicit "designer" drugs begin to appear, and our new pharmacogenetic department gives physicians the power to anticipate the right drugs and dosages to best treat their patients. Located in San Diego, Alcala is a laboratory of national reach and reputation. It is among the fastest growing labs in the country, dedicated to state-of-the-art science and the highest quality service.

Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The Company’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the Company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

AlivaMab Biologics is a biotechnology company based in San Diego, California, focused on therapeutic antibody discovery and development. The company provides integrated solutions to accelerate the creation of biologics, delivering fully human antibodies with a commitment to speed and reduced development risks. Their mission is to create efficient pathways for partners in the pharmaceutical and biotechnology sectors. The team at AlivaMab includes experienced professionals from leading global pharmaceutical companies, contributing to over 500 discovery programs and 35 clinical candidates. They utilize advanced technologies, such as the AlivaMab® Mouse platform, to generate high-quality antibodies and offer a range of services, including antibody engineering and target validation. AlivaMab collaborates with numerous top-tier pharmaceutical companies, with several of their antibodies currently in clinical trials.

Allakos Inc. operates as a clinical stage biopharmaceutical company. The company is developing antolimab (AK002) for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.

Allele Biotechnology and Pharmaceuticals, Inc. is a private, San Diego-based company that explores the mechanisms of biological processes to develop technologies and products for biomedical researchers. The company was founded by scientists and other professionals with the goal of advancing discovery and innovation. Our mission is to increase accessibility to innovative molecular biology research tools by offering cutting edge products at a reasonable cost, and providing excellent customer service in addition to the technical knowledge needed to facilitate their use. Our knowledgeable scientists and technicians are available to answer questions regarding any of our products. Over the past decade, Allele has become a reliable source for a wide variety of Molecular Biology reagents, superior fluorescent proteins, camelid derived nano antibodies (nAb), cellular reprogramming services and reagents, and immundiagnostic kits and various other products and custom services.

AltruBio is developing first-in-class immunomodulators to target diseases of the immune system. Our world-class global team brings a breadth of expertise in immunology and drug development to bring our biologic treatments to patients.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.

Focusing on generating innovative biological respondents with a unique mode of action coupled with conditionally activated characteristics, we handle high-value disease targets with huge upside potential, which are otherwise intractable for traditional targeting approaches.

Ambrx Biopharma Inc., a clinical-stage biologics company, focuses on discovering and developing engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers, as well as other multiple product candidates targeting immuno-oncology applications. In addition, it is developing ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient’s own immune system by targeting the ß and gamma receptors on the cytotoxic T cell; and ARX822, a fab-small molecule bispecific that is in preclinical development for cancers. Ambrx Biopharma Inc. has collaborations with various pharmaceutical companies, which include Bristol Myers Squibb Company; AbbVie Inc.; Astellas Pharma Inc.; and Elanco Animal Health. The company was founded in 2003 and is based in La Jolla, California.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

AmMax is a private biotechnology company focused on the clinical development of innovative cancer therapeutics. The Company strategically acquires oncology assets to develop into innovative and clinically meaningful products. It leverages its expertise in translational science to pursues first-in-class or best-in-class therapeutics with significant market opportunity. The company is focused on leveraging its CSF1R mAb platform licensed from Amgen, to launch multiple oncology products that address colorectal cancer with minimal residual disease (CRC MRD), tenosynovial giant cell tumors (TGCT), and an antibody-drug-conjugate construction for acute myeloid leukemia (AML) and solid tumors. AmMax has a very experienced management team, led by Dr. Larry Hsu, co-founder and former CEO of Impax Laboratories, Inc., which he successfully built into a fully integrated multi-billion dollar publicly traded pharmaceutical company. With broad experience across therapeutic areas and therapeutic modalities, the AmMax team is strong in execution and has collectively brought multiple BLAs, NDAs and MAAs to approval and commercialization. With a seasoned management team, a versatile technology platform and a robust pipeline, AmMax is poised to grow into a leading biotech company. For more on AmMax Bio and its pipeline, please visit the Company’s website at: www.AmMaxBio.com.

AnaptysBio ($ANAB) is a clinical-stage biotechnology company focused on transforming patient health by discovering and developing innovative immunology therapeutics. Our broad portfolio of immune cell modulators includes two checkpoint agonists in clinical-stage development. We are dedicated to making a difference in the lives of people living with autoimmune and inflammatory diseases.

AnaSpec, a subsidiary of Kaneka Eurogentec, is a globally recognized biotechnology company that manufactures and sells custom and catalog Peptides, Fluorogenic and FRET Assay Kits, Fluorescent Dyes, Amino Acids and more, for research use, drug discovery and diagnostic use. We also manufacture custom Peptide based starting materials for GMP applications. As a trusted and long-standing provider to the biopharmaceutical and diagnostic industries, academia, and governmental institutions, we aim to empower the scientific community in their endeavors to elucidate diseases and enhance health and well-being, through our quality proteomic products and services. Our team of experts strive for excellence with honesty and transparency on behalf of our customers. AnaSpec established in 1993 is certified to ISO 9001:2015.

Ancora Biotech LLC is a privately held company supporting the clinical development of three multi-specific antibodies. These three antibodies are held in separate spin-offs, namely: 1) TeneoTwo holds our clinical stage TNB-486 (anti-CD19xCD3) T cell engager for the safe and effective treatment of B cell cancers, 2) TeneoFour holds our preclinical TNB-738 (anti-CD38) enzyme inhibitor for the treatment of inflammatory and metabolic disorders in the elderly, and 3) TeneoTen holds our preclinical T cell engager (anti-HBVxCD3) for the curative treatment of chronic hepatitis B infections (CHB). TNB-738 is poised to enter Phase I clinical studies by early 2022 and we anticipate to select a clinical lead for CHB by mid-2022. Certain former executives and former shareholders of Teneobio, including Lightspeed Venture Partners and Sutter Hill Ventures, have formed Ancora Biotech to oversee all manufacturing and clinical development of these assets.

Angeles Therapeutics is a next generation cell and immune therapy company based on the technology licensed from the laboratory of its founder @PreetChaudhary. Angeles has developed a novel CAR-T and CAR-NK platforms that provide physiological TCR signaling and overcomes most of the limitations of current generation CAR-T. Most importantly, our platform is highly effective against solid tumors. Angeles has also developed one of the largest portfolio of CAR-T and CAR-NK in the world targeting more than 130 antigens covering cancer, infection and immune disorders. Our platform is fully compatible with autologous, allogeneic, universal and bispecific approaches. Angeles has recently entered a partnership with a global major pharmaceutical company and is looking for additional partnership opportunities for further development of its portfolio.

Annexon Biosciences is a clinical-stage biopharmaceutical company developing novel therapies for autoimmune and neurodegenerative diseases, including ophthalmic diseases.

Antibodies Incorporated is a biotechnology company that specializes in manufacturing and distributing monoclonal and polyclonal antibodies, diagnostic reagents, diagnostic kits, and developing ImmunoAssays.

Antibody Solutions is a privately held American contract research organization that helps biopharmaceutical companies advance their discovery of better diagnostics and therapeutics by delivering fit-for-purpose antibodies. The company provides comprehensive project management and technical support in a fee-for-service model. Antibody Solutions has expertise in immunology, immunochemistry, biochemistry, molecular biology, cell biology, transgenic animal platforms, flow cytometry, recombinant expression, and bioreactor technology. Antibody Solutions has served more than 500 clients, including all of the top 10 global pharmaceutical companies. Founded in 1995, the company is headquartered in Santa Clara, Calif. and works with clients worldwide. A leading developer of therapeutic, biomarker and critical reagent antibodies, Antibody Solutions provides elements vital for successful antibody discovery, including: Antigen design and generation Monoclonal and polyclonal antibody generation Monoclonal and polyclonal antibody production and purification Biological characterization (sensitivity, specificity, agonist/antagonist activity, internalization) Physico-chemical characterization (affinity, amino acid sequence, purity) Conjugation of antibodies and proteins Antibody engineering and recombinant expression Analytical methods development (ELISA, Flow Cytometry, PK/PD, ADA, Flourescence-Activated Cell Sorting) The company offers 24/7/365 online project management and tracking service.

Anwita Biosciences, Inc. is a clinical stage biopharmaceutical company headquartered in the San Francisco Bay Area. We are advancing our product pipeline of improved cytokines (Exenokines, Mableukins etc) and tumor-targeting antibody drug conjugates. Our lead product, Exenokine-21, has been accepted by China NMPA and the US FDA to initiate clinical studies. Our mission is to deliver transformative treatment options to improve the lives of patients with cancer and autoimmune diseases. We specialize in the discovery and development of optimized immunotherapeutics, leveraging our core expertise in cancer immunotherapy, bioinformatics, and target-based protein evolution.

Apeximmune's mission is to harness the power of the immune system to treat cancer and autoimmune disease. We focus on discovering and pioneering powerful therapeutic antibodies against innovative targets that shift the balance of immune cell activity and deliver lasting, transformative medicines.

Applied Biomics is a proteomics service company that provides top-quality, cost-effective, and full-line proteomics services to meet customers' research and discovery needs.

Advancing Gene and Cell Product Development Through iPSC and Genome Editing Technologies Applied StemCell strives to advance gene-editing and stem cell innovation for biomedical research and the biotechnology industry to assist in the development of breakthrough therapeutic approaches to cure intractable diseases. ASC is a trailblazing CRO/CDMO committed to building a complete iPSC-Gene Editing platform for the production of iPSC-derived products for gene and cell therapy research and development. With the integration of our unique iPSC approach and IP-based site-specific large cargo insertion technology, TARGATT™, we (1) develop immune-compatible master iPS cell lines and (2) deliver large DNA fragments to pluripotent cells that have proven differentiation capabilities. We stand at the forefront of the iPSC-based therapy revolution delivering research- and GMP-grade iPSC solutions along with various downstream assay services. Current Offerings: • iPSC Cell Line Models: iPSC generation, CRISPR & TARGATT™ genome editing, differentiation • Cell Gene Product CDMO: TARGATT™ iPSC Platform for allogeneic cell therapy products/GMP iPSC reprogramming, cell banking, gene editing, and differentiation • Bioproduction: TARGATT™ CHO cell system for antibody screening and bioproduction/TARGATT™ HEK293 cell system for library/antibody screening • Animal Models: Custom and off-the-shelf CRISPR & TARGATT™ mouse models For patent licensing, business development, and investment inquiries, please contact us at info@appliedstemcell.com.

Aptitude Vision is a biotechnology company that specializes in developing next-generation synthetic biomolecules for treating vision-threatening diseases by simultaneously targeting multiple pathological processes.

Drug discovery remains an expensive and time-consuming process. Promising compounds proceed through clinical trials only to have many fail before FDA approval. Aracari Biosciences aims to simplify this process by more accurately and efficiently evaluating promising drug compounds in a human tissue-on-a-chip model prior to clinical trials. Our​ proprietary, Vascularized Micro-Organ (VMO) platform is the first to contain a 3D, perfused network of living, dynamic human blood vessels that deliver nutrients and drugs directly to tissues just as in the body. Ask about our oncology models that incorporate multiple human tumor types within the vascularized tissue or our blood-brain barrier model for testing trans-barrier transport of drug compounds targeting the brain.

Arbor Vita Corporation (AVC) is a privately held company committed to making a difference by enabling early and accurate diagnosis and treatment of disease. The company has products on the market or in clinical studies to address global health challenges in the areas of HPV-induced cancer and infectious disease. AVC also has a pipeline of products in development.

Arcus Biosciences is an exciting growth company founded on the vision of creating best-in-class cancer therapies. We are an oncology-focused biopharmaceutical company leveraging its deep cross-discipline expertise to discover highly differentiated therapies and develop a broad portfolio of novel combinations addressing significant unmet needs. We are located in the San Francisco bay area, in the heart of the world’s largest biotechnology research hub. Arcus Biosciences offers a competitive compensation and benefits package, including aggressive participation in the growth of the company in the form of stock option grants. Arcus is an ambitious undertaking, and we fully expect our company to become a force in the discovery, development and commercialization of novel therapies for the treatment of cancer. Our employees enjoy operating in an exceptionally dynamic and cooperative environment in which the “rule book” has not yet been written.

Arda is taking aim at chronic diseases and aging by eliminating the pathogenic cells that drive these conditions.

We now know that immune cells – not only in the body’s periphery but especially in the brain – can produce autoantibodies that cause severe neurological and psychiatric diseases. Founded to explore the latest discoveries in autoimmune neuropsychiatry, Arialys Therapeutics is developing new precision medicines to specifically block pathogenic autoantibodies in the brain and meaningfully expand the treatment possibilities for neuropsychiatric disorders driven by autoimmune disease.

Aridis Pharmaceuticals is a late-stage clinical development company leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections. The company’s pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of antimicrobial resistant bacteria (AMR).

At Artiva, our mission is to deliver to cancer patients highly effective cellular immunotherapies that are also safe and immediately accessible. Towards this end, Artiva is advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, including CAR-NK cell therapies, that leverage the company’s unique manufacturing and engineering capabilities. Artiva is headquartered in San Diego.

Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmune and infectious diseases. Asher Bio is backed by Third Rock Ventures and is located in South San Francisco.

āshibio is developing novel therapies for patients with rare bone and connective tissue disorders that have the potential to prevent the onset of symptoms or slow the progression of disease.

Since our inception in January of 2006, Assay Biotechnology has been a worldwide contributor of industry-leading antibody and assay technologies, fluorescent dyes, quenchers, recombinant proteins and synthetic peptides. Located in the heart of California's San Francisco Bay Area, we have strived to answer the global need for high quality assay kits and immunological reagents used in academic and pharmaceutical research that formulate the basis of healthcare. For the first couple years after our founding, Assay Biotech established itself as an antibody manufacturer, catering specifically to large corporations through OEM partnerships. Since then, we have been emerging as a prominent assay and antibody source, expanding our reach to millions of researchers in over 50 countries around the world. We are determined to become one of the world's leading assay development and manufacturing companies, providing a multitude of ready-to-use assays, immunological reagents, molecular detection modules and biomarkers to support the most arduous academic and pharmaceutical research endeavors.

Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.  With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies.

Atengen is developing drugs that specifically target the tumor blood vessels of most solid tumors. The long-term goal is to develop a new generation of drugs that can be used in combination with existing cancer therapies to improve patient outcomes.

Athena Discovery is a contract research organization (CRO) for biotech and pharmaceutical companies specializing in non GLP drug discovery services with a focus on virology and immunology.

Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated disease and oncology. We leverage ATTOBODY, a novel biologics platform, to generate small format biparatopic binders that unlock the spatial aspect of target engagement. The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, exquisite specificity, and accelerated target internalization. Their small format and modularity offer fast tissue penetration, ease of engineering into bispecifics, and tunable half-life from hours to weeks. Collectively, these properties of ATTOBODIES expand the addressable target and epitope universe across disease areas and can offer stronger efficacy, faster speed to response, and an improved safety profile compared to traditional approaches. By utilizing our ATTOBODY technology, we will develop novel medicines that target unaddressed elements of disease, as well as offer better efficacy and tolerability. We envision a world where no patient is left behind.

Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Our proprietary pan-amyloid removal (PAR) therapeutics are designed to directly bind to and remove toxic amyloid in organs and tissues. By targeting the universal disease-causing pathology in all systemic amyloidosis diseases, PAR therapeutics have the potential to treat and reverse disease in patients with all types and stages of systemic amyloidosis.

ATUM is an industry-leading provider of life science tools and solutions. Founded as DNA2.0 in 2003, we were a pioneer in the application of machine learning to synthetic biology and currently hold multiple patents covering several technologies, including our first-to-market Leap-In Transposase® platform. Our integrated offerings include Gene Design & Synthesis, Protein Production, Cell Line Development, and Master Cell Banking — all powered by our Leap-In Transposase® and machine learning platform. This means a streamlined path from sequence to Master Cell Bank (MCB) with just a click, ensuring efficiency, regulatory compliance, and innovative solutions tailored to our clients' needs. ATUM is privately held and is headquartered in Newark, CA.

Aulos Bioscience is an immuno-oncology company revolutionizing cancer patient care through best-in-class IL-2 therapeutics computationally designed to exquisitely direct patients’ own immune systems toward killing tumor cells. Matching world-class machine learning from founder and partner Biolojic Design with an in-depth understanding of the immune system, Aulos’ initial clinical candidate, AU-007, has been designed to harness the power of a patient’s own IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated class of therapeutics. AU-007 has the potential to become a best-in-class treatment for solid tumors. The company was founded by Biolojic Design and ATP with $40M in Series A funding from ATP and is led by pioneers in the field of artificial intelligence, antibody development and cancer immunotherapies. For more information, visit aulosbio.com.

Research product distributor, Contract Services

Autonomous Medical Devices Incorporated (AMDI), with its principal place of business in California, employs a world class team of engineers, scientists, clinicians, and manufacturing experts dedicated to the development and manufacture of point-of-care diagnostic devices using breakthrough microfluidics, protein engineering, and data/cloud connectivity. AMDI will launch its first products from its ISO:13485 certified 110,000 square foot facility in Santa Ana, CA.

AvantGen is a biotechnology company dedicated in accelerating antibody-based therapeutics for their scientific partners by using innovative platforms. Based in San Diego, the fun and collaborative team is steadfast in this pursuit.

Aves Labs produces high-affinity, custom chicken IgY and other immunoreagents for biomedical research and antibody manufacturing.

Avid Bioservices (NASDAQ:CDMO), is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology, biopharmaceutical, and cell & gene therapy industries. With over 30 years of experience, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Avid Bioservices positions are accessible via the Avid Bio Careers page at https://avidbio.com/careers/.

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company’s lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases.

Aviva Systems Biology specializes in providing polyclonal and monoclonal antibodies, ELISA kits, proteins, and custom services for research needs. We manufacture 24,000 validated polyclonal antibodies and offer nearly 20,000 ELISA kits. Our custom laboratory services include protein expression and purification, antibody development, and ELISA development, validation, and production. Our head office is in San Diego, CA, we also have an office in Beijing, China. Both locations provide scientific support assisting researchers with a variety of proteomic objectives. Aviva provides unique tools for research associated to unique species and targets. The company's products are relevant to 10,000 unique species, 10,000 cellular processes, and 5,000 protein pathways. Research Areas Transcription factors, cancer, cardiovascular, cell biology, DNA damage and repair, epigenetics, signal transduction, cell differentiation, stem cell biology , and many more. Specialties Western blot, immunohistochemistry, ELISA, custom protein expression

AxisPharm is a San Diego based antibody drug conjugate (ADC) linker product and service provider. At AxisPharm, we focus on manufacturing novel ADC linkers, site specific molecular probes and advanced biochemical reagents. We also provide a variety of bio/chemical services worldwide, including custom synthesis and integrated drug discovery services.

The company providesservices inbioanalytic, molecular and cellbiology, in vitro and in vivo pharmacology.The company's capabilities include assay development and in vitro/in vivo pharmacologystudies forantibodies, small molecules, siRNAs, proteins, and gene therapy products.

BCN Biosciences is a privately held pharmaceutical company with core competency in oncology drug development. BCN is currently developing novel small molecule drugs for the treatment of cancer.

3/21/23- Acquired IsoPlexis Corporation (Nasdaq: ISO) then renamed to create PhenomeX. On Aug. 17, 2023, PhenomeX and Bruker entered into a merger agreement. Berkeley Lights is a leading functional cell biology company focused on enabling and accelerating the rapid development and commercialization of bio-therapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect™ chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain. Berkeley Lights’ Beacon® and Lightning™ systems and Culture Station™ instrument are for research use only. Not for use in diagnostic procedures.

BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases. BigHat is backed by Section 32, ‍Andreessen Horowitz, 8VC, Amgen Ventures, Bristol Myers Squibb, Quadrille, Grids Capital, AME Cloud Ventures, Innovation Endeavors and Gaingels.

Bio4t2 is a clinical stage bio pharmaceutical company developing novel single-target and combo-therapeutic CAR based cell therapies against solid cancers through its proprietary PrismCore platform that are fine-tuned to comprehensively target self-antigens in patients with solid tumors.

BioAtla is a leading San Diego-based biopharmaceutical company developing safer and more effective drugs for cancer. Its Conditionally Active Biologics™ (CAB) are designed to target and treat cancer with greater precision and fewer side effects.

Biocare Medical LLC is an innovator in automated immunohistochemistry (IHC) instrumentation, and the full range of reagents for IHC and in situ hybridization (ISH; RISH) testing. Biocare pioneered multiplex IHC detection which accelerates turnaround time, increases instrument productivity and reduces reagent consumption and cost by 50% or more. Multiplex IHC allows pathologists to visualize more than one marker on a tissue at a time, allowing higher confidence for critical differentiation. Biocare's intelliPATH FLX is the only completely open, continuous random access IHC instrument available. The company’s customers come from clinical and research environments that do tissue based testing and include histology laboratories, pharmaceutical and biotechnology companies; CROs; and academic, government and military labs. Biocare Medical offers an expanding portfolio of products for the rapidly growing cancer and infectious disease diagnostic and research markets. Biocare medical is headquartered and has manufacturing facilities in Concord, Calif., and has a global distribution network. See biocare.net and slidestainer.com for more information. NOTE: Biocare Medical, the Biocare Medical logo, and intelliPATH are trademarks of Biocare Medical LLC.

BioCheck develops and manufactures high-quality immunoassay kits for the worldwide healthcare markets in their cGMP and ISO 13485 certified facility in the San Francisco Bay Area. BioCheck also provides custom immunoassay development and contract manufacturing services to the diagnostic and research industries.

The heart of BioFluidica's CTC (Circulating Tumor Cells) system, is a highly efficient CTC capture bed, comprised of 50 to 500 sinusoidally-shaped channels. These channels are coated with antibodies, which isolate specific CTCs from whole blood. The antibodies are chemically immobilized onto the surfaces of the capture bed using BioFluidicas patented technology.

BioLegend develops antibodies and reagents for biomedical research, manufactured in our state-of-the-art facility in San Diego, CA.

BioMap is an AI for life sciences company, unmasking nature’s rules to generate proteins for a wide range of therapeutic and industrial applications. We build super-scale Foundation models supported by access to unrivaled computational power through our strategic collaboration with Baidu, with whom we share our Founder and Chairman, Robin Li. We supplement our AI capabilities with a leading team of scientists, disease experts and cutting-edge high-throughput labs which generate large volumes of high quality proprietary data for our AI models. We partner with pharma, biotechs and industry to enable their discovery ambitions across a wide range of therapeutic and synthetic biology modalities through access to our AI technology platform, with a variety of flexible collaboration models. Our mission is to leverage AI to radically improve lives.

Bionova Scientific is a dynamic, full service, biologics Contract Development and Manufacturing Organization (CDMO) on a mission to deliver the highest quality process development and manufacturing services to biologic drug development companies around the world. Bionova's renowned scientific expertise and dedication to its customers helps life changing therapies arrive to the market faster and more efficiently. At the heart of Bionova is a team of highly dedicated experts combining strong experience in cGMP biologics manufacturing and process development, with a technology-focused approach and a deep knowledge of the industry. From early stage research material generation to Process Development and GMP manufacturing, Bionova's teams are fully committed to helping their clients fulfill their objective of providing sustainable and affordable therapies to their patients.

Bioserv Corporation located in San Diego, California is a boutique cGMP contract manufacturing organization (CMO) serving the pharmaceutical, biotechnology, life sciences, medical device, and diagnostic industries since 1988. Bioserv’s core competency is manual filling which allows us to be very flexible and capable of handling small to medium batches effortlessly. Bioserv has a broad range of manufacturing suites to meet your production needs. Bioserv’s manufacturing facilities include certified Class 10,000 (Class 7 or Class C), Class 100 (Class 5 or Class A) areas, and Uncontrolled laboratory rooms. Whether a client is looking to move a drug product candidate into the pre-clinical setting, Phase I, Phase II clinic, or looking for basic reagent formulation and filling expertise, Bioserv has the experience and capabilities to get our clients there on time. We have filled a significant number of cGMP finished drug product lots for our clients to support their Phase I and Phase II clinical trial needs. We have a broad level of highly skilled production experts that have worked with very complex formulations, including liposomes, emulsions, nano-particles, small molecules, conjugates, and adjuvants. We understand that each product has its own unique set of manufacturing requirements. Bioserv is committed to making sure that those products are made with the highest Quality Standards each and every time. Work-From-Home Job Scam Alert It has been brought to our attention that job seekers are being contacted by scammers misrepresenting themselves as Bioserv recruiters. These scammers are contacting job seekers on LinkedIn or other job sites asking job seekers to apply for fake work-from-home positions. Please be advised that Bioserv does not generally offer work-from-home positions and all job listings are available here: https://sorrentotherapeutics.com/careers/. Any communication regarding recruitment will be done via email domain ending in @sorrentotherapeutics.co

BioVision is now part of Abcam. BioVision is a privately held Life Science company headquartered in the beautiful San Francisco Bay area. Founded in 1995, BioVision specializes in the supply and integration of high quality imaging technologies to support research. In August 2021, Abcam acquired BioVision for $340 million, and it is now part of Abcam.

The mission of Bluejay Therapeutics is to develop innovative cures for infectious diseases with the first target indication of chronic HBV infection. Bluejay has exclusively licensed global rights to advance several HBV programs, including a best-in-class anti-HBsAg monoclonal antibody.

Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. Bolt’s technology is appropriate for a broad spectrum of antibodies targeting tumor antigens expressed on all types of cancer and therefore applicable to many types of patients, including those who are refractory to the current generation of checkpoint inhibitors. The company is led by a team with extensive oncology drug discovery and development experience. Bolt was founded by Dr. Ed Engleman, and its platform is based on technology exclusively licensed from Stanford University. The company is financed by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com.

With 30 years of expertise, Boster Bio is committed to producing high-quality antibodies and ELISA kits at the best value for researchers worldwide. Our global distributor network extends beyond 30+ countries and delivers rigorously validated antibodies, ready-to-use kits, and reagents that have received over 60,000 citations. At Boster, our customers' research is our priority. Our mission is to help customers achieve their research goals so that they can stay on the cutting edge of research. To honor our customers' goals, we choose to uphold high quality standards by manufacturing our antibodies and ELISA kits in our very own facilities from start to finish for strict monitoring, efficiency, and optimization. Let us become your partner in research. Get better results with Boster. For more information, please visit www.bosterbio.com.

BroadPharm is a leading customer-focused biotech company. We are dedicated to manufacturing and supplying high-purity PEG Linkers, Click Chemistry Tools, ADC Linkers, PROTAC Linkers, Drug Delivery Lipids, and Labeling Reagents to our clients worldwide. Founded in 2009, BroadPharm takes our customer needs as our highest priority. We have over 8,000 PEG Linkers, Click Chemistry tools, ADC Linkers, Lipids, Fluorescent Dyes, and Nucleosides. In addition to our broad catalog selection, we also offer IP-protected custom synthesis and bio-conjugation services for our clients in the pharmaceutical and biotech industries. We provide timely technical support to address our client's needs and offer technical advice for the best use of our new products. With our strong expertise in modern chemistry along with innovative and novel Lipid & PEG technology supported by state-of-the-art equipment, BroadPharm can help our customers accelerate their research through cost-effective and efficient solutions.

Broadwing Bio is advancing antibody therapies to treat common causes of vision loss. Focused on genetically validated targets, our goal is to develop best-in-disease therapies to meaningfully preserve eyesight for glaucoma and geographic atrophy patients.

Developing innovative therapeutics to materially improve the lives of patients. We strive to be transparent and open in our goals, plans, and progress.

Building a smarter roadmap for precision therapeutics.

Celemics is a Next Generation Sequencing (NGS) full solution provider based on target enrichment technology. We confidently offer custom target enrichment panels and high-quality pre-set panels, covering fields such as Inherited Diseases, Oncology, Immunology, and Pathogen Diagnostics. With 13 years of experience, we will provide the best solution for your Targeted Sequencing. [Products/Services] OncoRisk (Hereditary Cancer) | CancerScreen (Somatic Cancer) | Custom Target Enrichment Panel | Whole Exome Sequencing | Clinical Exome Sequencing | BRCA 1/2 | PharmacoScreen | Comprehensive Respiratory Virus | Agrigenomics

Cenna Biosciences is revolutionizing Alzheimer's treatment with proprietary small peptides and molecules that inhibit beta amyloid production. The company is focused on developing disease-modifying drugs for Alzheimer's disease using a proprietary novel mechanism.

Centivax’s mission is to accelerate the world’s transition to a post-pathogen humanity.

Resident company JLabs San Diego focused on the development of immunotherapy for substance abuse.

CG Oncology, Inc. (Nasdaq: CGON), is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative oncolytic immunotherapies to live with dignity and have an enhanced quality of life. Our lead candidate, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. Cretostimogene grenadenorepvec is also in a Phase 2 study in combination with KEYTRUDA® (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with cretostimogene grenadenorepvec in combination with OPDIVO® (nivolumab).

CHO Plus is creating regulatory compliant genetically engineered mammalian cells to be used by biopharmaceutical companies for therapeutic protein manufacturing. Early proof of concept experiments demonstrate CHO Plus cells to be 4.5-fold more productive than parent cells in model system. The CHO Plus approach includes patented methods for genetically engineering mammalian cells; proprietary and patented targeted transfection technology; and efficient clone screening technology.

Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of new approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform.

Coagulant Therapeutics seeks to address acute bleeding, a significant area of unmet medical need and includes the indications post partum hemorrhage, intracranial hemorrhage, traumatic brain injury and blunt trauma.

Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics. We are building a leading oncology company backed by in-house expertise and an established infrastructure from our diversified portfolio of FDA-approved biosimilar products. If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at http://www.coherus.com/careers/ for a list of career opportunities.

ConfometRx is a leader in G protein coupled receptor (GPCR) structural characterization and analysis and GPCR-targeted drug discovery.

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company’s lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/2 clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and stimulate various immune cells, as well as Phase I clinical trial of CPI-006 for COVID-19; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2-inducible T-cell kinase, that is Phase I/Ib clinical trial.

CTK Biotech is a biotechnology company that specializes in medical diagnostics for healthcare applications.

CytomX Therapeutics, Inc. is committed to changing the treatment of cancer with our novel Probody® therapeutic platform. We have a broad pipeline comprised of five clinical-stage programs, with even more in development. Our commitment to transforming lives with safer, more effective therapies is driven by our curiosity and passion for innovation, and our belief that by acting with integrity in an honest, respectful, ethical manner, we have the power to change lives. Our workplace embodies collaboration, open communication, celebrating our successes and holding each other to the highest possible standards. CytomX embraces diversity and seeks to enhance and maintain our culture of equity and inclusion which encourages individuals to be themselves, feel involved, respected and connected. We at CytomX believe that we benefit from each other’s ideas and experiences. We accept our differences and learn from one another, improve together, and embrace change to achieve our corporate and individual objectives. This belief applies to how we work together at CytomX, how we work with others outside CytomX, how we represent CytomX in our communities, and how we endeavor to bring our scientific innovations to a diverse patient population. CytomX acknowledges the importance of diversity, equity and inclusion initiatives and that they require an evolving and ongoing commitment. CytomX is an equal opportunity employer and does not discriminate against any individual or potential candidate because of race, color, religion, sex, national origin, sexual preference or any other legally protected category. CytomX is located in South San Francisco, California, the birthplace of biotechnology. Learn more about us and how we are advancing science to treat cancer differently at www.cytomX.com.

Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco.

Diagnostic BioSystems is a leading developer of specialty Immunohistochemistry reagents. The company is dedicated to high quality antibody production and development of novel multiplex staining reagents. Building on its strong global presence, Diagnostic BioSystems produces novel, clinically relevant tools for pathology market including: monoclonal and polyclonal antibodies, a wide range of detection systems and ancillary reagents for high quality immunostaining. Custom Monoclonal and Polyclonal Antibody Production Services include peptide synthesis, in vitro and in vivo antibody production, purification and conjugation. Diagnostic BioSystems is an FDA registered medical device manufacturer, operating under FDA 21CFR Part 820 Quality System Regulations and certified under ISO 9001:2008 Quality Management System International standards, manufacturing CE marked medical devices, for use in the European market.

DNARx is a company developing multiple therapeutics for major unmet medical needs, with demonstrated vaccine capabilities as well as protein expression. The company has been awarded a DARPA contract for up to $10.7 million to develop medical countermeasures against biological threats.

Dren Bio is a Foster City, CA based biotechnology company, developing power protein-based technologies to deplete pathogenic cells and agents in numerous diseases.

Eigen Therapeutics is a biotechnology company developing therapies that make cancer easier to find and eliminate. Eigen is focused on the development of 'priming' therapies that improve efficacy while reducing the toxicity of small molecule therapies.

Electra Therapeutics is a clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer.

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor’s lead investigational candidate, ENV-101, is an inhibitor of the Hedgehog (Hh) signaling pathway in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The company’s second investigational candidate, ENV-501 is a human epidermal growth factor 3 (HER3)-targeted antibody-drug conjugate (ADC) for the treatment of HER3-positive solid tumors.

EnGen is an early-stage biotechnology company pioneering a new approach to preventing and treating influenza. We're developing an effective, easy-to-manufacture, shelf-stable universal flu vaccine that confers long-term immunity to all Type A influenza strains—including those which cause seasonal flu and influenza pandemics. Seasonal flu causes 250,000 to 500,000 deaths every year. The CDC and other experts have cautioned that we are extremely vulnerable to the catastrophic occurrence of a global flu pandemic—on a scale that could far exceed both COVID-19 and the Spanish flu of 1918. In its Global Influenza Strategy (2019–2030) report, the World Health Organization has declared the development of a universal flu vaccine as an urgent need—but the unique nature and genetic makeup of the influenza virus poses a challenge to researchers focused on influenza treatment and vaccination. To address these issues, EnGen Bio is developing universal vaccines for Type A flu prevention. Effective for vaccination in both the $6B human and $0.5B veterinary markets, our antibodies also demonstrate potential for therapeutic treatment of influenza, with an additional $2B prospective market. If successful, our efforts will eradicate flu pandemics and dramatically decrease the global burden of illness and disease caused by influenza.

Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The company’s proprietary War-LockTM platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics.

Ensigna Biosystems is a contract research organization that provides cutting-edge molecular pathology and genomic services to the biopharmaceutical industry. By combining traditional pathology services with genomics, Ensigna Biosystems is able to characterize biological samples based on protein expression, mRNA levels and mutational status, thus enabling the development of targeted therapies and the implementation of personalized medicine.

EpiBiologics is building a next-generation protein degradation platform that targets membrane and extracellular proteins. EpiBiologics was founded in 2022 based on the pioneering work from academic founder Dr. Jim Wells of the University of California San Francisco (UCSF). The Company’s proprietary EpiTAC platform is a modular antibody-based system that enables the precise degradation of disease-driving membrane and extracellular proteins in a tissue-specific manner. Headquartered in San Mateo, EpiBiologics is backed by leading healthcare investors and aims to develop first-in-class and best-in-class targeted therapies across multiple therapeutic areas.

Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to pioneer new products with a mission to dramatically improve the lives of patients with severe autoimmune and inflammatory diseases who continue to suffer with high unmet medical needs. By bringing treatments designed to restore the balance of the immune system, we hope to restore the balance of life for patients in need. Our lead product candidate, itolizumab, is a first-in-class monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the activation and trafficking of pathogenic effector T cells that drive inflammation in a number of diseases. We believe itolizumab may have broad therapeutic utility and our current pipeline is focused on developing itolizumab as a best-in-class treatment for multiple severe immuno-inflammatory disorders – this includes acute graft-versus-host disease, SLE / lupus nephritis and uncontrolled asthma.

Eureka Therapeutics is a privately held biotechnology company located in the San Francisco Bay Area, focused on breakthrough immunotherapies for the treatment of cancer. Utilizing our antibody drug discovery and engineering technologies, we are advancing safe and effective therapies for targeting previously inaccessible cancer antigens. We have built an early stage pipeline of innovative drugs, with the most advanced candidates at pre-clinical stage. Eureka Therapeutics is a leader in the discovery of novel antibody immunotherapies. We utilize a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancer antigens. In collaboration with Memorial Sloan-Kettering Cancer Center, we were the first-to-demonstrate in vivo efficacy of a human IgG1 antibody against an intracellular cancer antigen. Our most advanced program is at preclinical stage and being developed in partnership with Novartis.

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company’s products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.

EXONBIO is a recombinant antibody and recombinant protein company. SPIN (Single Plasma Cell Interrogation) Technology for rabbit recombinant monoclonal antibody (rrMAb) development.

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.

Fortis Therapeutics is an immuno-oncology biotech company focused on developing new antibody drug conjugate therapies against CD46 for the treatment of late-stage prostate cancer and multiple myeloma. FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics

GenCirq is a biotechnology company that is developing a novel class of bacterial therapeutics with the latest advances in synthetic biology.

About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or patientinfo@gene.com. Community Guidelines: 1. We want to foster positive conversation and diverse community around the issues we are passionate about. To that end, we remove profanity, content that contains credible threats or hate speech, content that is aimed at private individuals, personal information meant to harass someone, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.

As a multinational antibody manufacturer, GeneTex's primary goal is to provide bioscience researchers with thoroughly validated reagents to accelerate their discovery. Established in 1997 in San Antonio, Texas by scientists with expertise in clinical oncology, cancer biology, and infectious disease, the company's initial focus was breast cancer biology and prognostic marker research. This evolved to incorporate a comprehensive portfolio of immunological reagents used by scientists probing the underlying mechanisms common to many forms of cancer. GeneTex's catalog has since expanded to offer a broad and diverse selection of antibody products covering a full range of research areas. GeneTex is proud to offer the highest quality antibody reagents supported by extensive research, development, and validation. We are committed to the highest standards of product performance.

Reagents, Kits, Antibodies

GigaGen, a subsidiary of Grifols, is advancing transformative antibody drugs for immune deficiency, infectious diseases and checkpoint resistant cancers by leveraging industry-leading, single-cell technologies. GigaGen’s novel technology platforms uniquely capture and recreate complete immune repertoires as functional antibody libraries. This approach has enabled the creation of first-in-class recombinant polyclonal antibody therapies for the treatment of infectious diseases. GigaGen’s lead oncology asset, GIGA-564, is an anti-CTLA-4 monoclonal antibody that has demonstrated improved anti-tumor efficacy in vivo through a unique mechanism of action. GigaGen is leveraging its proprietary technology platforms for the continued discovery of novel recombinant polyclonal drugs and monoclonal antibodies to treat life-threatening diseases.

GlyTR Therapeutics Inc. was co-founded by Professor Michael Demetriou and Dr. Raymond Zhou in 2016 to accelerate the application of GlyTR immunotherapy to treat cancer in humans. GlyTR overcomes many of the shortcomings of current immunotherapies by binding to never-before targeted tumor-associated glycans expressed in virtually all types of cancer. GlyTR Therapeutics Inc. has been incubating at EvoNexus in Irvine and has received support by UCI’s Applied Innovation Center located at The Cove.

GondolaBio is a clinical-stage biopharmaceutical company focused on developing next-generation therapeutics for genetic diseases. Originally launched as BridgeBioX, a subsidiary of BridgeBio, GondolaBio secured $300M in private financing from external investors in 2024 and became an independent company within the BridgeBio ecosystem. The company aims to leverage cutting-edge biological research to create breakthrough medicines addressing high unmet needs across multiple therapeutic areas, including neurology, pulmonology, cardiology, nephrology, and endocrinology. Located on the Stanford Life Sciences campus, GondolaBio fosters a unique hybrid environment where top scientists from around the world collaborate with senior leadership and advisors, blending industry expertise with academic innovation.

Process, analyze, and annotate genomics and biomedical data at scale using containerized workflows.

Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate which is in Phase I/2 clinical study for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.

GT Biopharma, Inc. (GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager platform. The Company's lead oncology drug candidate, GTB-3550, is a novel, first-in-class, tri-specific natural killer cell engager for the treatment of various cancers. GTB-3550 is designed to address limitations of current NK cell-engager therapies by engaging NK cells to attack tumor cells, while also activating T cells to increase their anti-tumor activity. The Company is also developing OXS-3550, a bispecific scFv recombinant fusion protein that targets and binds to the human epidermal growth factor receptor 2 (HER2) and the low-affinity Fc gamma receptor IIIa (CD16) on human immune effector cells. GT Biopharma is headquartered in Brisbane, California.

Develop instruments and methods for quantifying stability, purity, and quality in protein therapeutics and cell and gene therapy products.

Helicore Biopharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics to address obesity and related metabolic conditions. The company is advancing a portfolio of next-generation treatments with a novel approach to glucose-dependent insulinotropic peptide (GIP) antagonism. Helicore's proprietary platform leverages monoclonal antibodies that bind circulating GIP ligand, designed to improve the efficacy, dosing, and tolerability of anti-obesity therapies. Helicore is rapidly advancing a differentiated portfolio that may deliver superior treatment outcomes through enhanced efficacy, tolerability and convenient dosing regimens. Following the close of a $65M Series A financing in January 2024, Helicore is well-positioned to drive progress in this critical area of unmet need. For more information, visit www.helicore.com.

Hexagon Bio is a biopharmaceutical company pioneering the discovering novel payloads for antibody-drug conjugates (ADCs) to address critical unmet needs in oncology. Leveraging a proprietary platform, the company mines cytotoxic small molecules from microbial genomes for use as ADC payloads. Advances in DNA sequencing have enabled the identification of both existing ADC payloads—such as topoisomerase and tubulin inhibitors—and novel payload mechanisms targeting essential cancer pathways such as protein translation. Hexagon Bio is advancing a pipeline of next-generation ADC candidates with novel payloads designed to treat a wide range of solid tumors and hematological malignancies.

Hinge Bio, Inc. is a privately-held biotechnology company leveraging its powerful GEM-⁠DIMER™ platform to develop therapeutics that address the problems of resistance, inadequate efficacy, and side effects in the fields of cancer, inflammatory disease and infectious disease. The GEM-DIMER™ technology uniquely enables (i) cooperative binding to disease targets allowing for orders-of-magnitude enhanced activity and (ii) greater degrees of multivalency and multispecificity than possible with conventional approaches, to produce molecules with entirely new functionality for superior safety and efficacy.

Iconic Therapeutics is a biopharmaceutical company that focuses on developing therapies targeting Tissue Factor in angiogenesis, inflammation, and malignancies.

We're a leading biotechnology company, providing streamlined or custom-tailored services for global clients in pharmaceutical, biotechnology industries, and academia. We've been a privately held family business since 1999, and have grown into a leading mammalian Contract Research, Development, and Manufacturing Organization (CRDMO). The CRDMO approach allows us to cover the entire spectrum of pre-clinical and clinical services - from the initial stages of target discovery and development, to cell line development, and manufacturing of mammalian therapeutic proteins, up to 1000 L scale. In 2023, we worked with more than 100 drug or vaccine development companies globally, producing more than 2400 different proteins. Clients trust us for custom-tailored solutions in every stage of drug substance development.

IgGenix is an early-stage, venture backed biotechnology company founded on breakthrough advances in Steve Quake’s laboratory at Stanford in collaboration with allergy clinician and researcher Kari Nadeau. We have exciting opportunities for enthusiastic, self-motivated, and highly organized individuals to join the growing team at IgGenix in South San Francisco, CA.

About IGM Biosciences, Inc. IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites, compared to conventional IgG antibodies with only 2 binding sites. We have created unique IgM antibodies with high selectivity, affinity, and avidity that may redefine what is possible for therapeutic antibody medicines. We are committed to exploring how the unique structure and binding properties of the IGM antibody can improve outcomes for patients with these serious conditions. The Company also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology, immunology, and inflammation targets. For more information, please visit www.igmbio.com. Imvotamab in Autoimmune and Inflammatory Diseases Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. We believe that Imvotamab, with its 10 binding units for CD20, may successfully bind to CD20 expressing B cells with more power (avidity) compared to an IgG bispecific antibody with only one or two binding units for CD20. Our preclinical studies suggest that Imvotamab may offer the potential for deeper depletion of B cells, including those in low CD20 expressing cells, than currently approved antibody therapies. We are evaluating Imvotamab in Phase 1b clinical trials of Imvotamab in severe systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and idiopathic inflammatory myopathies (myositis).

ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.

Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a private, clinical-stage oncology company dedicated to discovering and developing novel biotherapeutics targeting myeloid cell inhibitory receptors. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies. Immune-Onc has a differentiated pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB). Immune-Onc’s focused platform approach has led to the development of several promising therapeutics across various stages of development. Those include IO-108, an antagonist antibody targeting LILRB2 (also known as ILT4), in Phase 1b/2 clinical development for solid tumors, and IO-202, a first-in-class antagonist antibody targeting LILRB4 (also known as ILT3), in Phase 1b clinical development for the treatment of acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors. Additional assets in Immune-Onc’s pipeline include IO-106 (first-in-class antagonist antibody targeting LAIR1), IO-312 (a novel bispecific antibody targeting LILRB4 and CD3), and undisclosed immunology and oncology programs. For more information, please visit www.immune-onc.com.

ImmunityBio (previously NantKwest (NASDAQ: NK)) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells. ImmunityBio is uniquely positioned to implement precision cancer medicine, with the potential to change the current paradigm of cancer care. Natural Killer cells are ancient cells in the human body designed to recognize and detect cells under stress or infected. Our “off-the-shelf” activated Natural Killer (NK) platform have the capacity to destroy cancer and virally infected cells from the body. The safety of our NK cells as well as their activity against a broad range of cancers have been tested in multiple phase 1 clinical trials in the United States, Canada and Europe. In addition to our NK cells capability to be administered in the outpatient setting as an “off-the-shelf” living drug, it serves as a universal cell-based therapy without need for individualized patient matching. Moreover, our NK cell based platform has been bioengineered to incorporate chimeric antigen receptors (CARs) and antibody receptors to further optimize targeting and potency in the therapeutic disease. Our targeted therapeutic areas include: (1) cancer, focusing on bulky hematological cancers and solid tumors as well as cancer stem cells, (2) infectious diseases, including viral, fungal and bacterial infections, and (3) inflammatory diseases, ranging from rare inherited diseases to more prevalent autoimmune disorders.

Quality is our Heritage - Service is our Passion Immuno Concepts is a privately hold company that specialises in the manufacturing of in vitro diagnostics for Autoimmune Diseases since 1980. Our product portfolio comprises reagents and instrumentation such as a unique automatic microscope scanning system for immunofluorescent slide tests. Hospital labs all over the globe and major lab chains trust in our quality and service.

Aristo Vojdani, PHD, MSC, CEO Immunosciences Lab. Inc. located in Los Angeles is part of the Medical and Diagnostic Laboratories Industry.

IncellDx is a molecular diagnostics company dedicated to revolutionizing healthcare one cell at a time. By combining molecular diagnostics with high throughput cellular analysis, we focus on critical life threatening diseases such as COVID-19, HIV/AIDs, lung cancer, breast cancer, bladder cancer, HPV/cervical cancer, head and neck cancer, ovarian cancer, hepatitis, and organ transplant infections. Our proprietary diagnostic method provides specific molecular details about each and every cell. This technology now made available through IncellDx, is capable of revolutionizing the field of molecular diagnostics, one cell at a time.

Indapta's allogeneic g-NK cells have highly potent ADCC activity, making them the ideal therapy to combine with IgG1 monoclonal antibodies, ADCs, or innate immune cell engager molecules.

Indi Molecular is developing protein catalyzed capture (PCC) agents as a small synthetic molecule replacement for antibody-based therapeutics. PCCs are poised to play a central role in therapy given their ability to be deployed as both a precision in vivo PET diagnostic and as a targeted therapeutic. For radiotherapy this dual role is accomplished by choice of the complexed radionuclide sharing the same chelation chemistry. Chemotherapy can similarly be specifically delivered to diseased cells by the protein catalyzed capture technology. The company launched in 2013 with a $1.8 million seed round, followed by an $11.5 million Series A in 2017.

Infinimmune is a biotechnology company pioneering a novel approach to antibody drug discovery and development. Founded by a world-class, multidisciplinary team of scientists and technologists, Infinimmune is reinventing antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. These truly human antibodies are designed to drug new and existing targets with improved safety and efficacy. Infinimmune will deploy its holistic approach to build its own pipeline of drug candidates and partner with pharmaceutical companies to advance their antibody programs, fill their pipelines, and reach new patients and new indications.

The mission of iNFixion Bioscience is to develop drug therapies to treat and prevent the progression of all symptoms associated with Neurofibromatosis Type 1 (NF1), a rare genetic disorder impacting approximately 2.5M people worldwide. iNFixion's unique approach to NF1 is to correct a key underlying genetic ‘mechanism of action', namely the lack of functional Neurofibromin protein, by enhancing the affected person's natural ability to both produce and maintain healthy Neurofibromin protein. By correcting this root cause mechanism, we believe that a fundamental and preventive impact on disease symptoms, and disease progression, will be achieved.

Inhibrx is a clinical-stage biotechnology company dedicated to helping people with life-threatening conditions through scientific innovation and excellence. They have a pipeline of novel biologic therapeutic candidates developed using their protein engineering expertise.

Inmagene is a global clinical-stage biotechnology company developing novel therapeutics for I&I diseases. The company’s highly differentiated clinical-stage pipeline has multiple candidates with best-in-class potential. The lead asset IMG-007, a non-depleting anti-OX40 mAb, is in two global Phase 2a clinical trials in atopic dermatitis and alopecia areata. IMG-004, a non-covalent reversible BTK inhibitor is in a Phase 1 multiple ascending dose (MAD) study. IMG-008, an in-house developed long-acting anti-IL-36R mAb is entering global Phase 1 clinical development.

Innovative NeuroTechnologies, Inc. (INT) is a development-stage biotechnology company operating in “virtual mode” that is currently pursuing a pipeline of novel biologically-based and disease-modifying therapeutic solutions to prevent, delay, or mitigate the underlying dementia or cognitive decline associated with a spectrum of neurodegenerative disorders referred to as tauopathies, which includes: • Alzheimer’s disease (AD), • Frontotemporal dementia (FTD or Pick’s disease), • Chronic traumatic encephalopathy (CTE) or dementia pugilistica, • Progressive supranuclear palsy (PSP), • Corticobasal degeneration (CBD), • Familial form of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and • Parkinson's disease dementia (PDD). The pathology of these seemingly disparate conditions is similar in that they involve dysregulation of the Tau protein and development of neurofibrillary tangles (NFTs), synaptic dysfunction, and/or neuronal loss, which underlie the observed dementia or cognitive deficits. Unfortunately, there are no effective therapies presently available for this spectrum of disorders, and neurodegenerative tauopathies remain a very significant socioeconomic burden and tremendous unmet medical need worldwide.

At InvivoGen, we strive to provide life scientists worldwide with innovative, high quality and reliable reagents. As specialists in cell culture engineering and innate immunity, we are passionate about designing, developing, and bringing to market new tools and services for cutting-edge research. At our three regional headquarters — in Toulouse (France), San Diego (USA) and Hong Kong (China) — and through our dedicated multilingual customer support staff, we can provide researchers around the globe with the reagents and product information that they need to make the scientific breakthroughs of tomorrow. InvivoGen is a privately held company founded by university researchers in 1977 in Toulouse, France. Since then, we have gradually expanded with the opening of InvivoGen San Diego, in 1997, and InvivoGen Hong Kong, in 2014. Our unparalleled skills in microbial fermentation enable us to produce a wide range of bioactive molecules, including ultra-pure antibiotics, novel mycoplasma treatments and the largest available collection of pattern recognition receptor agonists, from various micro-organisms. Over 25% of InvivoGen’s employees hold a PhD in biology or chemistry. Through specialized R&D teams, they work together seamlessly to design, produce and validate novel plasmids, cell lines, vaccine adjuvants and synthetic ligands for research in areas as diverse as gene therapy, molecular immunology and vaccination. Moreover, based on our first-hand knowledge of innate immune receptor signaling pathways, we have devised an ever-expanding collection of reporter cell lines, including cytokine reporter cells and knockout (KO) cell lines for high-priority innate immune targets. Scientists depend on InvivoGen for quality, consistency and reliability. Whatever research challenges you are facing, count on InvivoGen to provide you with the tools and solutions that you need.

Ionpath delivers high definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate discovery and improve human health. Ionpath’s MIBI™ (multiplexed ion beam imaging) Platform breaks through the limitations of traditional IHC, enabling deep understanding of the tissue microenvironment with highly multiplexed quantitative single-cell analysis. With MIBI technology and the expertise of world class pathology and data science teams, Ionpath provides actionable insights to translational and clinical researchers at leading pharma, biotech, and research organizations in immuno-oncology, immunology, neuroscience and infectious disease research.

Jasper Therapeutics is a biotechnology company focused on targeting mast cells and stem cells to treat chronic diseases. Their mission is to make a significant difference in the lives of patients suffering from these conditions.

A business unit of JSR Corporation, JSR Life Science LLC is changing human health as a strategic partner and pathfinder for the life sciences industry. Rooted in a history of materials innovation, JSR LS provides specialized products, materials, and services to biopharmaceutical companies and academic researchers. Together with its world-class affiliates, JSR LS offers best-in-class integrated services that de-risk molecule selection, accelerate biologic development timelines, increase clinical success rates, and develop novel in vitro diagnostics. JSR LS’s global network of affiliates includes Crown Bioscience, KBI Biopharma, Inc., and MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. The company operates R&D and applications labs, manufacturing facilities, and sales offices worldwide.

KAER Biotherapeutics is a preclinical aerosol drug delivery company addressing the needs of respiratory ailments in clinics and hospitals. KAER is primarily focused on the provision of surfactant aerosol therapy for patients in respiratory distress related to the absence of sufficient active lung surfactant. These patients include prematurely born infants whose lungs are not producing sufficient low surface tension surfactant to enable their airways to fully open and support adequate respiratory function. Neonatal Respiratory Distress Syndrome, NRDS, is the major cause of mortality in prematurely born neonates. At any age, but especially in the elderly, insults to the lungs and body can induce acute respiratory distress. Acute respiratory distress syndrome, ARDS, results from abnormal surfactant production and inflammation-induced degradation of surfactant. When this is the result of a direct insult to the lungs, such as pneumonia or smoke inhalation, it is denoted acute lung injury, ALI. ALI can rapidly deteriorate into ARDS. There are no approved drugs for patients with ARDS. Despite the best life support, 40% of these patients die. KAER developed patented enabling aerosol generation, processing and delivery technology to address these needs. KAER's SUPRAER technology aerosolizes liquids containing the surfactant or other active pharmaceutical agent and delivers them as concentrated pure fine particle solid-phase aerosols suitable for deep lung deposition. SUPRAER is differentiated by its ability to aerosolize viscous fluids and suspensions of high molecular weight agents. High masses of fine particle therapeutic aerosols therapies can be rapidly administered at clinically relevant doses. KAER is seeking partners to facilitate the rapid implementation of this the aerosol delivery technology for the treatment of respiratory distress, IPF, hospital acquired pneumonia, TB, NSCLC and other debilitating lung diseases.

Kairos Pharma is focused on developing cutting-edge therapeutics for cancer patients that reverse the inhibitory effects of cancer on the immune system. By doing so, we seek to transform the way cancer is treated by positively impacting patient outcomes while maintaining quality of life.

KDx Diagnostics Inc. pioneers the revolutionary URO17®bladder cancer test, poised to redefine non-invasive detection. As the co-inventor and exclusive licensee of this groundbreaking technology, KDx Diagnostics Inc. has garnered FDA Breakthrough Device Designation, CE-IVD certification, and MHRA approvals for the URO17® test. With extensive testing on thousands of samples and validation through respected peer-reviewed journals, URO17® demonstrates improved sensitivity and specificity as compared to other diagnostic tests and procedures. The URO17® urine test presents a compelling alternative to invasive diagnostics and costly imaging techniques for routine monitoring in the US, while diagnosis and monitoring for outside USA of bladder cancer, potentially setting a new gold standard in bladder cancer diagnosis and monitoring.

As a company focused on rapidly advancing next generation transformative assets, we leverage our expertise to efficiently progress programs to clinical proof of concept. Guided by rigorous science and a commitment to addressing unmet medical needs, our experienced team collaborates with global partners and key opinion leaders to accelerate the delivery of life changing antibody-drug conjugates (ADCs) that aim to conquer cancer.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in researching, developing, and commercializing therapeutics to treat retinal diseases in the United States and international markets. Its lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy, including diabetic macular edema, as well as for macular edema due to retinal vein occlusion. The company’s preclinical stage product candidate includes KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate conjugate to treat neovascular retinal diseases with an inflammatory component. Its early research pipeline includes KSI-601, a triplet inhibitor for the treatment of multifactorial retinal diseases, such as dry AMD and the neurodegenerative aspects of glaucoma. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is based in Palo Alto, California.

Lassen Therapeutics is developing novel, best-in-class biotherapeutics to improve the lives of patients suffering from serious diseases.

Lassogen is developing a new therapeutic modality based on lasso peptides that we are programming to treat difficult diseases such as cancer and autoimmune disorders.

Levena Biopharma is a global ADC CRO/CDMO dedicated to advancing Antibody Drug Conjugate programs from discovery to the clinic and beyond. In 2013, Sorrento acquired Concortis Biosystems, establishing Levena as an independent, wholly-owned subsidiary of Sorrento Therapeutics to offer the scientific community access to our leading-edge linkers, payloads, and site-specific conjugation technologies. Our mission is to collaboratively develop conjugates that maximize the therapeutic potential of our clients' native or engineered antigen-targeting biomolecular carriers (antibodies, proteins and nucleic acids) and advance precision medicine options for patients with unmet clinical needs. We welcome discussing your projects and our capabilities at our world-class facilities in: -- San Diego (R&D Headquarters, 2013) -- Suzhou (CMC and cGMP, 2017) Levena provides small and large scale proof-of-concept (POC) conjugation services as well as complete ADC characterization using advanced analytical tools such as HPLC (HIC, SEC, RP), iCIEF and LC-MS, quality assessment (Drug-to-Antibody Ratio, purity via SDS-PAGE, aggregation, endotoxin, residual drug) and in vitro pharmacology for cytotoxicity studies. Expanding on IP from Concortis starting in 2008, we continue to maintain and grow our comprehensive, in-house portfolio of leading-edge ADC solutions, enabling Levena's world-class chemistry & conjugation teams to efficiently deliver constructs with unsurpassed quality and therapeutic potential. Our proprietary and non-proprietary ADC solutions include Linkers, Payloads, L-P chemistries and site-specific conjugation platforms [C-Lock™, K-Lock™ and C-Lock™/K-Lock™ for dual-drug delivery], enabling efficient development of mechanistically-defined ADCs with exacting, reproducible performance for safety, efficacy and clinical success.

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. Visit our technical products: omniab.com, captisol.com, vernalis.com and ltptechnology.com.

List Labs specializes in the production of native toxins, recombinant proteins, bacterial fermentation, assay development, contract manufacturing, and biotherapeutics. List Labs produces C. difficile toxin A and toxin B, shiga toxins, cholera toxin, anthrax toxins (PA, LF, and EF), pertussis toxin, diphtheria toxin, CRM197, tetanus toxin, staphylococcal enterotoxin B, botulinum toxins as well as several types of lipopolysaccharides (LPS) or endotoxin for purchase by the research community.

LiVeritas Biosciences enables biopharma companies to fast track drug research & development (R&D) process through mass spectrometry (MS) and digital transformation. We offer unparalleled sense of urgency and quality of work to empower our partners in delivering patient-centric outcomes through: • Curated analytical test packages effective in rapidly advancing drug candidates in the development pipeline including (1) drug design optimization, (2) process development and characterization, (3) accelerating novel drug candidates path to Investigational New Drug (IND) • Partner-centric software solutions that streamlines analytical operations, CMC strategies, and drug product knowledge management; and • Industry expertise with milestone focused biotech startup backgrounds grounded in big biopharma core competencies.

LTZ Therapeutics is an immunotherapy-focused global biotech company pursuing innovative therapies in oncology and autoimmune diseases. Pioneering a novel myeloid engager platform that is guided by reverse translational science, emerging disease biology, and leveraging the power of myeloid cell subsets, particularly macrophages, which offer tremendous potential as an effective therapy to improve the lives of patients with the bold aim to one day eliminate cancer.

We develop regulatable antibodies that vastly improve patient outcomes resulting from their application as next-generation immunotherapeutics, diagnostics and immunoaffinity reagents

Mach5 Therapeutics is a privately held biotechnology company founded by several former ValenzaBio and AlmataBio team members. The company plans to advance innovative therapeutics to transform patient care.

MBrace Therapeutics is a privately-held biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets. MBrace is supported by a world-class investor syndicate, including TPG, Avidity Partners, Cowen Healthcare Investments, Venrock and Alta Partners.

Medikine is a biopharmaceutical company with a mission to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a disruptive and versatile drug discovery platform that generates modular “PEPTIKINES” that are smaller in molecular size than, and structurally unrelated to, the natural cytokine proteins they emulate. These PEPTIKINES are readily amenable to further enhancement for desired pharmacokinetics or added pharmacologic features. Medikine’s lead product candidate MDK-703, which is planned to enter clinical trials in 2022, is an Fc-fusion protein containing an IL-7 PEPTIKINE, which emulates the beneficial properties of IL-7, a cytokine critical to maintaining T cell response. An important feature is its avoidance of the generation of neutralizing antibodies to native IL-7. Medikine has also identified novel PEPTIKINES that activate the IL-2/15βγc receptor and is exploring their use in bispecifics with differentiated profiles, including an IL-7R and IL-2/15Rβγc dual agonist and a cell-targeted IL-2/15Rβγc attenuated agonist.

Meditope Biosciences, Inc. is in possession of a revolutionary antibody platform technology called “SnAP” (Site-specific, novel, Antibody Platform), which can turn antibodies into a LEGO-like system. The power, elegance, and simplicity of SnAP allows for a broad range of molecules – toxins, proteins, radiolabels, other antibodies – to be ‘snapped’ on or off an antibody with predictability, precision and control. Meditope is using this technology to develop a preclinical pipeline of compelling cancer drugs including two new immuno-oncology product for prostate and bladder cancers.

Meissa is a private biotech company focused on the advancement of vaccines for respiratory viruses. Meissa was founded on proprietary technologies employing reverse genetics for rational design of more effective live attenuated vaccines. The technology is exclusively licensed from Emory University and Children’s Healthcare of Atlanta. Dr. Moore, together with Dr. Roderick Tang, a vaccine biotech expert, co-founded Meissa. They are supported by a team with extensive experience in all aspects of vaccine development. Meissa is currently a resident company at the Johnson & Johnson Innovation – JLABS in South San Francisco.

Mitera is a maternal-fetal medicine (MFM) telehealth company. We help inform and educate our patients about their pregnancy-related risks and options through obstetrical screenings and at-home genetic testing kits, empowering them along their family-forming journey.

Molecular Depot is a biochemical company located in San Diego, California that specializes in developing research tools such as Specialty Bacterial Culture Media, Antibodies & Antigens, Enzymes & Proteins, Chemical Compounds & Molecular Conjugates, Research Kits, Reagent Stabilization Solutions. They also provide consulting and research services related to their products.

MDS is a contract research organization that provides molecular diagnostics and toxicology services to pharmaceutical and research institutions.

Multitude Therapeutics (MTX) is a spinoff company created by Abmart to leverage its unparalleled target and antibody discovery capability for cancer immunotherapy. MTX focuses on developing novel antibody-drug conjugates (ADC), CAR-Ts and immuno-oncology antibodies for solid and hematological tumors. MTX's therapeutic programs are based on novel cancer and immune cell surface targets discovered by monoclonal antibody arrays (Human Membrane Proteome MabArrayTM or HMP-MabArrayTM) powered by the exceptional antibody discovery capabilities built at Abmart.

Nammi Therapeutics, Inc. is an immuno-oncology company based in Los Angeles that is developing platforms and products that selectively activate anti-tumor immunity within the tumor microenvironment while minimizing systemic activation. By reducing systemic activation of the immune system, Nammi expects to improve safety and enhance the ability to combine multiple immune modulators. Nammi's lead product candidate, QXL138AM, is a Masked Immunocytokine (MIC) targeting a masked interferon to the tumor antigen, CD138. In addition to the MIC platform, Nammi has also developed a nanoparticle platform to deliver Immune Modulating Prodrugs (IMPs) using their Nammisome technology. Multiple Nammisome clinical candidates have also been selected for development.

NanoCellect is committed to empowering every scientist to make discoveries one cell at a time, by ensuring high cell viability required to advance cell-based research. We develop and deliver microfluidic based solutions that are affordable, compact, and easy-to-use. Our expanding portfolio of instruments and consumables enable biomedical scientists to analyze and sort cells required for drug discovery, single cell-omics, cloning, antibody discovery, and basic research.

Nascent Biotech, Inc. (OTCMKTS:NBIO) is a public company, formed in March 2014, to continue development of Pritumumab, a human monoclonal antibody created by a number of leading scientists who have developed various monoclonal antibodies and cytokine treatments for oncology indications. Pritumumab recognizes a unique and proprietary antigen expressed on the surface of cancer cells and is being developed to treat brain and pancreatic cancers, both unmet clinical needs. NBIO’s clinical premise is that the most effective way to treat disease is to modulate (boost or suppress) the human body’s natural ability to generate an immune response. Often referred to as “immunotherapy”, the scientific approach is based upon two discrete types of regulatory molecules, monoclonal antibodies and cytokines that can be combined to maximize therapeutic effectiveness in a variety of diseases. Monoclonal antibodies (mAbs) are naturally occurring proteins that bind with exquisite specificity to molecular structures on the surface of target cells. Monoclonal antibodies are, collectively, the fastest growing products in the entire pharmaceutical industry. In 2005, no mAbs were among the top 10 selling drugs in the world. By 2010, they were 5 of the top 10 selling drugs, accounting for $34.1 billion in annual sales and 45% of total sales of the top 10. By 2013, 6 of the top 10 selling drugs worldwide were mAbs accounting for $50.1 billion in sales – 66% of top-10 total sales worldwide.

NGM Bio is a research-driven, clinical-stage biopharmaceutical company with a passion to improve the lives of those struggling with serious diseases. Our expertise in drug discovery and translational development, coupled with the significant resources from our partnership with Merck, is driving development of transformational medicines that dramatically improve human health. Our initial R&D focus has been to develop a portfolio of high-impact therapeutics for the underserved patient populations who suffer from cardio-metabolic and liver diseases. We believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of other disease areas as well, such as cancer. NGM Bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. As we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. Coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles.

NinthBio is a software company serving Biotech. Our flagship product is "Homology Path", an application that designs the oligos for DNA synthesis. The value is how few oligos are needed to build a a group of similar DNA sequences. Think of the DNA you would need to test for a protein engineering campaign, or to optimize the affinity of an antibody. All require similar but ultimately unique DNA. Our customers can improve their Design, Build, Test Learn Cycle by 15X all while decreasing their DNA spend 10 fold. Researchers are rethinking where and what they are willing to explore given the power of Homology Path, opening the door for rapid and higher value discovery. Want to see how this can help your initiatives; request a demo token to access the capabilities of Homology Path.

Nitrase Therapeutics is a pioneering biopharmaceutical company deploying its unique NITROME platform to unlock the therapeutic potential of nitrases, a new class of enzymes that it discovered, to develop a pipeline of therapies against a broad variety of diseases. The medicines that Nitrase Therapeutics is developing will target these enzymes and potentially help slow or halt the progression of a wide variety of diseases in which nitrases and nitro-substrates play a role, including Parkinson’s and cancer. Nitrase Therapeutics (under the former name Nitrome Biosciences) has been widely recognized and has won multiple awards including the prestigious Target Advancement grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF).

Novodiax is a biotech startup dedicated to advancing cancer and autoimmunity diagnostics through innovative rapid immunoassays. Our revolutionary ihcDirect® assays are listed for in vitro diagnostic (IVD) use and provide immunohistochemistry (IHC) results in as little as 10 minutes on frozen tissues! They also provide workflow benefits for formalin-fixed, paraffin-embedded (FFPE) tissues, helping reduce assay time by up to 40-60 minutes. ihcDirect works by directly conjugating primary antibodies to our proprietary and sensitive polymerized horseradish peroxidase (polyHRP) detection system, thus delivering immunoassays for histology and cytology (2020) that: - Are lightning fast (~10 minutes) - Require minimal lab space and no specialized equipment - Can be performed at room temperature - Are simple to perform like H&E tests, yet provide the sensitivity and specificity of immunoassays Our assays are also perfect for helping you advance your research (see our ihcPrime™ and Q-Stain® products and custom services), develop cutting edge companion diagnostics (CDx), and more. Let's partner together to make that happen! Visit our website or contact us to learn more. www.novodiax.com sales@novodiax.com

Our mission is to develop effective and affordable preventive vaccines for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders. Using our universal vaccine platform for Alzheimer’s, our goal is to induce antibody titers high enough to penetrate the blood-brain barrier and prevent pathological plaques, fibrils, and oligomers to delay disease onset in cognitively unimpaired people at risk of Alzheimer’s.

Nuvig Therapeutics is a science-driven research and clinical development organization focused on translating novel scientific insights into therapies for patients with chronic autoimmune and inflammatory diseases.

OmniAb is a leading-edge antibody discovery company that provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening. The company's discovery platform brings a high level of expertise and innovation to therapeutic antibody discovery.

Oncternal Therapeutics is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with large unmet medical need. By leveraging pathways absent or minimally expressed in normal cells or tissue, we aim to inhibit cancer cell growth while reducing potential harm to healthy cells. We are pursuing trials in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), breast cancer, and Ewing sarcoma. Looking forward, we intend to rapidly broaden our pipeline and invest in the development of our innovative therapies across multiple cancers.

Ouro Medicines is dedicated to developing immune reset therapeutics for people living with chronic immune-mediated diseases. Our approach is focused on leveraging T cell engagers in B cell mediated diseases to achieve immune resets that enable durable remissions without ongoing immunosuppression for patients. Based in San Francisco, Ouro was founded by Monograph Capital in partnership with GSK. We are also backed by leading investors TPG, NEA, Norwest and more.

Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute myeloid leukemia, myeloid dysplastic syndrome, and multiple solid tumors by leveraging our proprietary NK cell engager (TriKE) platform technology. (NASDAQ: GTBP)

Contract R & D

Partillion Bioscience is an early stage life science company aiming to democratize advanced single-cell assays with its award-winning nanovial platform. Our novel platform allows the rapid compartmentalization and analysis of millions of single cells to probe biological function such as secreted proteins. The validated technology underpinning Partillion’s products has been featured in notable journals such as Science Advances, Advanced Functional Materials, and Lab on Chip and received industry accolades, winning the 2020 SLAS Innovation Award.

The term PathnSitu describes the study of disease in its original state. We at PathnSitu carefully study various pathological characteristics of carcinoma in situ to aid in the diagnosis of cancer through novel techniques and quality reagents. The team of PathnSitu consists of world class scientific advisors and hands-on technical advisors that bring over two decades of global tissue diagnostics experience directly to the customer. The company is founded upon a fresh, dynamic perspective that brings energy and motivation to develop quality products for better patient care. Our dedication to your lab will streamline your staining process and reduce the turnaround time, all at affordable pricing. Our company motto is to make cancer diagnosis effective and affordable. We are ISO 9001:2008, ISO13485:2003 certified company and we practice USFDA and GMP, GDP and GLP.

Our goal is to find innovative therapies that address significant unmet medical needs for patients with inflammatory, rare and specialty diseases, and cancer. Notice to recruiters All recruitment vendors (temporary staffing agencies, placement services, and professional recruiters) are prohibited from contacting our employees. In order to be an authorized vendor partner for Peak Bio, all such organizations must have a formal written agreement with Peak Bio’s Human Resources Department.  Notice to Recruiters; Peak Bio’s receipt or acceptance of an unsolicited resume submitted by vendor organization does not constitute an actual or implied contract between Peak Bio and such organization. Peak Bio will not pay a fee to any vendor that does not have such agreement in place.

PeproMene Bio, Inc is a clinical-stage biotech company in Irvine, California. We are committed to developing novel therapies to treat cancers and immune disorders. Our CAR T cells targeting an innovative tumor antigen (BAFF-R) for treating a broad range of B cell malignancies have a great potential to overcome the tumor relapse caused by antigen loss. We are working on bringing hope to those patients with such unmet medical needs.

Phanes Therapeutics, Inc. is a biotech company focused on innovative drug discovery and early development in immuno-oncology and eye disease. Our mission is to become a major source of innovation in the biopharma industry. The way we focus on science, the disruptive technologies we develop, and the revolutionary approaches we bring help open up new possibilities in drug discovery. At Phanes, we bring innovation that illuminates the path to cure. Cancer cells cunningly evade the immune system using many different mechanisms. We believe that only when the full potential of the human immune system is unleashed, tumors can be effectively treated or even cured. One of our therapeutic approaches is to boost both the innate and adaptive immunity with monoclonal antibodies and bispecific antibodies. We are also interrogating non-immune pathways that may play key roles in the tumor microenvironment for their potential in developing novel therapeutics. In addition to a strong pipeline, Phanes has developed disruptive technologies that enable drug discovery. Phanes' three novel technology platforms are designed to build native IgG-like bispecific antibodies that enhance drug-like properties. The company has three technology platforms: PACbody™ (for building native IgG-like bispecific antibodies), ATACCbody™ (for building bispecific antibodies with modulated activities) and SPECpair™ (for building bispecific antibodies with enhanced manufacturability). For more information, please visit www.phanesthera.com

Phoenix Pharmaceuticals Inc. provides over 7,000 peptide-related products to researchers worldwide: ELISA kits, Peptides, Custom Peptide Synthesis, & Antibodies. We specialize in the fields of Obesity, Cardiovascular, Alzheimers, and Diabetes.

Planet Biotechnology produced the first plant-made antibody, or “plantibody”, ever tested in a clinical trial. We are focused on discovering, developing and commercializing new antibody-based therapeutic and preventative products through cultivation of genetically modified green plants to meet significant underserved medical needs. Scientists at Planet Biotechnology identify and develop promising antibodies and receptor-antibody fusion molecules for the treatment and prevention of infectious diseases including emerging diseases and bio-threat agents. We routinely adapt our antibody and receptor-antibody products for rapid production in non-food, non-feed green plants grown in greenhouses. This same approach has been used by others to produce three anti-Ebola virus antibodies that are undergoing clinical trials in Africa.

Polynoma LLC is a biotechnology company based out of 11230 Sorrento Valley Rd, San Diego, CA, United States.

Prellis Bio is hiring Immunologists! We are expanding our Externalized Immune System, EXIS™, platform with applications in antibody discovery, immunogenicity, and vaccine screening all in the same platform. Prellis Biologics, Inc. is a privately held company based in the San Francisco Bay Area, CA. Apply at www.prellisbio.com.

Primordial Genetics is a biotechnology company focused on improving the performance of bio-production systems, and enabling the development and improvement of microbes and enzymes used in pharmaceutical & industrial manufacturing and in agriculture. We develop and use whole-genome synthetic biology genetic tools to create efficient production organisms and industrial enzymes. Function Generator, the company’s flagship technology, enables rapid and flexible development of novel biological products and traits required for microbial production of amino acids, proteins, chemicals and other useful compounds. The technology is highly effective at overcoming ‘genetic black box’-type biological productivity or enzymatic activity bottlenecks that have resisted other attempts at improvement.

Profluent is an AI-first protein design company. Founded in 2022, we develop deep generative models to design and validate novel, functional proteins to revolutionize biomedicine. Based in Emeryville, CA, we are backed by leading investors including Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures. To learn more about our mission to decode the language of life with AI, visit profluent.bio.

ProMab Biotechnologies, Inc is a revolutionizing biotechnology company that integrates cutting edge technologies to serve the global biomedical research community. We specialize in recombinant proteins, antibodies and engineered cell lines on which we are known to have built a superior reputation for quality and reliability. Our commitment to Excellence is exemplified by our newest service where we provide mRNA-LNP product and services that allows a swift and effective response to emerging infectious diseases. Join us in shaping the future of biotechnology and scientific progress. For more inquiries, visit our webiste: https://www.promab.com/. Email: info@promab.com

At Promega Corporation, creativity and connection drive discovery and innovation. We celebrate scientific discovery and the creative application of science to solve problems. Interactions with our customers, partners and vendors are central to everything we do, and we value those relationships. We seek out and build connections across the globe and in our local communities because creative problem solving requires a network of diverse ideas and viewpoints. We develop and evolve technologies and instrumentation in collaboration with scientists and researchers around the globe. From simple cloning vectors used to address fundamental questions in biology to bioluminescent assays that help us monitor food safety and water quality, we work side-by-side with our partners in academic, industrial and government institutions to bring the best minds to bear on the toughest questions. Since 1978, we have done this all with a steadfast commitment to sustainable business models that protect our environment, inspire and develop our employees as individuals, support the wellbeing and growth of our communities, and strengthen our relationships with our customers. With 16 branches around the world, Promega products are used by a global community of life scientists who are asking fundamental questions about biological processes as well as by scientists who are applying scientific knowledge to diagnose and treat diseases, discover new therapeutics, and use genetics and DNA testing for human identification.

ProSci Incorporated | Trusted Antibody Solutions for 25+ Years At ProSci, we understand that breakthrough research depends on reliable antibodies and a partner who genuinely cares about your success. For over two decades, we’ve supported scientists worldwide with high-performance monoclonal, polyclonal, and recombinant antibodies—combining rigorous science with personalized service. Our offerings include 35,000+ catalog products, such as RUO biosimilars for cost-effective oncology and diagnostic research, alongside fully customizable antibody services. Whether you need polyclonal antibodies with flexible immunizations, recombinant monoclonals for batch-to-batch consistency, or traditional monoclonals for precision, our team delivers end-to-end support, including peptide design assistance and custom labeling (HRP/biotin). With 25,000+ projects completed, we prioritize quality through robust QA/QC processes and rapid turnaround times (typically 2–6 months). What sets us apart is our partnership approach. We work side-by-side with researchers developing therapeutics, diagnostics, or basic science tools to simplify supply chains, provide expert guidance, and deliver trusted antibodies—backed by our 25-year legacy. Strategically, we focus on expanding custom services for unique research challenges, leveraging our RUO biosimilar portfolio for preclinical studies, and strengthening collaborations with CROs and diagnostic developers. Now part of the Genesee Scientific family, we remain committed to making exceptional antibody solutions accessible—because your research advances science for everyone. Let’s collaborate. Contact us today to discuss your project needs.Our commitment to excellence is reflected in our customizable antibody services, innovative products, competitive pricing, and exceptional technical support. ProSci is dedicated to advancing biological research by offering top-tier research tools and solutions. Discover more at prosci-inc.com

Protillion Biosciences is a Stanford University spinout commercializing disruptive technology for therapeutic antibody and binder discovery. We have developed an entirely novel, powerful and high-throughput protein display platform designed to revolutionize traditional approaches to the design and development of protein-based drugs.

PTM Therapeutics is striving to discover new targets and develop new therapeutics for the treatment of chronic diseases and cancer by targeting post-translational modifications.

QED Bioscience is a biotechnology company that specializes in designing and manufacturing antibodies, offering top-quality products and services to support clients in their research.

QLSF Biotherapeutics is an innovative immuno-oncology startup company in South San Francisco. Our research and development are focused on a diversified oncology portfolio, with strong financial and clinical development support from a leading pharmaceutical company.

Rakuten Medical, Inc. is a global biotechnology company developing and commercializing precision, cell-targeting investigational therapies on its AlluminoxTM platform, which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Outside of Japan, Alluminox therapies have not yet been approved as safe or effective by any regulatory authority. The company’s first drug developed on the Alluminox platform, ASP-1929, has received approval from the Japanese Ministry of Health, Labour, and Welfare, and is currently the subject of a global phase 3 clinical trial for recurrent head and neck cancer. Rakuten Medical is committed to its mission to conquer cancer by delivering our innovative treatments as quickly and safely as possible to as many patients all over the world as possible. The company has locations in 6 countries, including the United States, where it is headquartered, Japan, Taiwan, the Netherlands, Switzerland and India.

Rani Therapeutics is a clinical-stage biotech company that has developed a platform technology to enable oral delivery of biologic drugs. Millions of patients with chronic conditions require biologic drugs, the vast majority of which must be injected. We have developed the RaniPill™ technology to replace subcutaneous or IV injections of biologics with an oral pill. The RaniPill™ capsule is designed to deliver an injection to the intestinal wall, where there are no sharp pain receptors, and has achieved bioavailability similar to subcutaneous injections. We believe oral versions of biologics will have the potential to transform medicine and improve outcomes for the millions of patients who currently rely on chronic self-injections.

Regen BioPharma Inc. is a publicly traded biotechnology company focused on developing innovative treatments using autologous cell therapies, RNA and DNA-based immunotherapy and small molecules in the immune-oncology and autoimmune disease space.

Neuropathic pain arises as a direct consequence of a lesion or disease affecting the somatosensory nervous system. Patients suffer from hyperalgesia, an increased sensitivity to non-painful stimuli such a few hairs brushing against their skin (allodynia). Hyperalgesia causes a burning or prickling sensation (paresthesia), or shooting, stabbing, electric shock-like pain – episodic or continuous. Neuropathic pain may persist for months and years after nerve injury. It affects over 560 million people worldwide and 100 million adults each year in the U.S. Examples include, but are not limited to, phantom limb pain in amputees, lumbar (back) pain with radiculopathy, diabetic neuropathy, shingles, and complex regional pain syndrome (CRPS). E.g., there are 12 million cases of back pain per year in the U.S. alone. Releviate Therapeutics is addressing unmet needs in Chronic Pain. Current treatments are largely based on suppressing inflammation using steroids, anti-depressants and anti-seizure drugs that cause unwanted drug side-effects, or drugs that lead to addiction, such as opioids. We offer first-in-class antibodies, the development of which is rooted in actual pain pathology and directly inactivating pain pathways. Releviate directly targets pain. There are two major products: RLVT-9-01 (anti-MMP-9 antibody) and RLVT-14-02 (anti-MMP-14 antibody). RLVT-9-01 targets MMP-9, which recent discoveries implicate as a switch that turns on acute neuropathic pain. RLVT-14-02 targets MMP-14, which has been implicated in triggering chronic neuropathic pain.

We, at REMD, are a biopharmaceutical company focused on discovering and developing cutting-edge bio-medicines to treat cancer, diabetes and other diseases. REMD develops world class, high quality, and efficient medicine by uniting top American medical scientists and elite Chinese pharmaceutical assets, leveraging the world's most advanced research and development technologies.

Rezolute is a clinical stage biopharmaceutical company dedicated to developing transformative therapies for patients suffering from debilitating metabolic disorders. They are focused on advancing their pipeline of drug candidates to address unmet medical needs in diabetes, obesity, and other metabolic disorders.

Rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases. For more information, visit: www.rezolutebio.com.

At Rondo Therapeutics we believe that our success as a company starts with building a culture based on teamwork, trust, career growth, and a sense of fun. If you are a fearless scientist driven to make new discoveries and you value collaboration, respect, and working in a team environment, then we want to hear from you! Join us in our mission to create novel molecules that bring new hope to cancer patients while advancing your career in a merit-based culture. Rondo Therapeutics is committed to advancing the field of immuno-oncology, with a focus on treating solid tumors that fail to respond to current therapies. Our solution is to create a new class of bispecific antibodies that safely engage the immune system to initiate and sustain a robust anti tumor response.

Santa Ana Bio is a precision immunology company leveraging multi-omics platforms and antibody engineering to deliver targeted therapies to patients with autoimmune and inflammatory diseases.

In vitro diagnostic company, specializing in the production of antibodies, controls, blockers including HBR. - Clean Rooms - Filling - Finishing - Packaging - Sub-Assembly - Inventory Space - Kit Manufacturing - Lyophilization - Antibody Production - Medical Device Manufacturing

Scripps Laboratories is a biotechnology company that specializes in bulk manufacturing high quality proteins and immunoreagents for the diagnostic industry and research community.

Seranova Bio is an early-stage company dedicated to the creation of groundbreaking therapeutics. Our proprietary REAP (rapid extracellular antigen profiling) technology and analytics platform enable the discovery of the functional immune interactions that drive health and disease. We were founded in 2020 by Fred Hutchinson Cancer Center professor and serial academic entrepreneur Aaron Ring. Located in the vibrant biotech hub of South San Francisco, we are proudly supported by leading investors Foresite Capital Management and The Column Group.

Serimmune is an immune intelligence company that provides a holistic view of immunity to identify environmental factors in disease and health. Serimmune’s Serum Epitope Repertoire Analysis (SERA) technology platform applies bacterial display peptide libraries, next generation sequencing, machine learning and custom bioinformatics to reveal the many diverse antigens stimulating immunity.

Shasqi is a privately held, clinical stage biopharmaceutical company who is focused on bringing the advances of click chemistry to help people fight their cancer. The Click Activated Protodrugs Against Cancer (CAPAC™) Platform is a therapeutic modality based on click chemistry, which utilizes the biocompatible chemical reaction between an attenuated trans-cyclooctene-modified protodrug and a tetrazine-modified biopolymer. The biopolymer is injected in the desired tumor, which then captures and activates an infused protodrug precisely at the tumor site.

Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.

Silver Lake Research Corporation is a biotechnology company based in Monrovia, California, founded in 1992. The company specializes in the development and manufacturing of diagnostic test kits, focusing on rapid point-of-care diagnostics. Their proprietary EAP™-derived monoclonal antibodies ensure high accuracy and sensitivity, comparable to laboratory assays. The company offers a range of diagnostic test kits, including those for water quality, air contaminants, and urine analysis. Their Watersafe® line features a highly sensitive water lead test and comprehensive bacterial detection. Additionally, Silver Lake supplies bio-engineered proteins for therapeutic drugs and diagnostic components to other companies. They operate one of the largest independent automated production facilities for lateral flow tests in the U.S. Silver Lake Research emphasizes consumer safety, targeting concerns related to waterborne pathogens and carcinogens. They also provide white-label components for third-party diagnostic kits, indicating strong partnerships within the industry. The company operates from two locations, with general operations in Monrovia and administrative functions in Irwindale.

A pioneering, proven approach to antibody discovery that delivers actionable leads by capturing all available data.

Skye Bioscience, Inc. is a pharmaceutical company focused on unlocking the pharmaceutical potential of the endocannabinoid system, initially with a focus on modulating the system for the treatment of glaucoma and other diseases. They are developing proprietary cannabinoid derivatives for therapeutic use.

At Sony Biotechnology, our flow cytometry and imaging products reflect our full commitment to produce and support high quality, innovative products to support advanced biomedical research. Founded in 1995, we are based in San Jose, California with affiliate offices in Japan, China and Europe. Innovation Research and Development as well as engineering teams are based in Japan. Their innovative approaches and technical know-how is incorporated into our product platforms has been recognized in patents as well as numerous technology and design awards. For example, to improve stability, our systems allow direct monitoring of particle flow status using technology originally developed for the Blu-ray disk that delivers error free performance while operating at very high speed. In conventional flow cytometers, this accuracy largely depends on skillful operators. To deliver very low noise electronics, our systems incorporate technologies that have brought pure, true sound to music. This Sony know-how reduces signal noise from the electric circuit currents to achieve very low noise electronics so that rogue signal noise does not get in the way of delivering accurate results to scientists. Importantly, our innovations also come from looking beyond the conventional made possible by constant sensing and deep study of advanced technologies for superior solutions to customer challenges. Our use of microfluidics and spectral analysis are two examples of this innovative approach to product design and development.

Sorrento Therapeutics is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical CAR-T therapies targeting solid tumors.

Spyre Therapeutics combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for inflammatory bowel disease.

When protein –based biotherapeutics first came to the market the importance of purity was the highest outmost objective and the cost was not the major factor. We are living in the age of biosimilars where the purity is given but the cost of production is critical to succeed. Sterogene's focus is to provide chromatography resins and other products that can result in significant savings to our customers. Our resins are extremely stable, NaOH cleanable and provide long cycle life. We have resins that are validated for over 100 cycles and used in the production of licensed pharmaceuticals. Our Direct Capture technology saves significant cost for our customer due to elimination of costly filtration steps and overall resulting in higher purity and lower production time. Our mission is to provide our customers with innovative products of the highest quality, enabling them to efficiently develop and manufacture safe and efficacious products. We can achieve this by developing custom purification products that meet the regulatory requirements of governing bodies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), while allowing significant cost-saving for our customers.

Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline.

Founded in 2004, Sundia MediTech Company, Ltd. is a leading pre-clinical contract research organization (CRO) providing a comprehensive and integrated portfolio of high-quality drug discovery and development services. Sundia's experienced R&D and international management team possess extensive experience across the fields of chemistry (custom synthesis, library design and synthesis), medicinal chemistry, biology (in vitro and in vivo), DMPK, pre-clinical studies, as well as pharmaceutical development (process research and development, API manufacturing, pre-formulation and formulation, analytical as well as QA/QC, CMC and IND filing) services. Sundia's primary research facilities, which include standard and kilo-labs, an animal facility, a pilot plant and other supporting facilities, are located in Shanghai (Zhangjiang Hi-Tech Park), Shijiazhuang and Taicang. For more information, please visit us at www.sundia.com or email us at info@sundia.com.

Surf Bio is a preclinical biopharmaceutical company that is transforming how antibodies and biologics are delivered to patients. Surf SnapShot™ technology enables mAb concentrations of 600+ mg/mL and delivery of a dose over 1,000 mg in a single, standard autoinjector shot. SnapShot’s™ ultra-high concentration formulations are uniquely powered by Surf Bio’s proprietary polymer, enabling the most accessible and patient-friendly subcutaneous delivery of mAbs and biologics. For more information about Surf Bio, visit www.surf.bio

Surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal

Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.

Synthetic Design Lab is built to revolutionize antibody-drug conjugates (ADCs) with its novel SYNTHBODY™ therapeutic platform. The platform is engineered to optimize targeted payload delivery ≥10x compared to current ADCs, potentially improving upon the efficacy, safety, and overall versatility of earlier ADCs.

Tachyon is accelerating innovative science to develop first-in-class therapeutics against significant new drug targets in cancer biology. Tachyon operates with a dedicated internal core development team and a world-class external network of expertise to achieve one goal - advance our programs with speed, innovation, quality and scientific integrity.

Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Tallac’s pipeline of immunotherapy candidates are derived from the company’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic administration. Several TRAAC molecules are in various stages of discovery and preclinical development.

At Tegmine we target glycoproteins, which are a hallmark of numerous solid cancers and drive aggressive disease. We’ve engineered a system to generate revolutionary new antibody-based therapies for cancer which dramatically increase efficacy while reducing toxic side effects. Our proprietary TegMiner™ platform enables the discovery of unique cancer epitopes and allows us to develop these life-changing new antibodies for patients with unmet needs.

Telesis Bio is empowering researchers to accelerate the creation of novel synthetic biology solutions to address some of humanity's greatest challenges. With our breakthrough automation solutions for biological synthesis and expertise in DNA biology, we enable rapid, accurate, and reproducible writing of DNA and mRNA for wide-ranging biological applications. Around the world, innovators are leveraging Telesis Bio's technology to overcome current bottlenecks in synthetic biology workflows and advance the discovery of cutting-edge solutions for health and technology. We are proud of our growing collaborations with partners that include premier academic research institutions, emerging start-ups to nearly all of the Top 25 Biopharma companies. Telesis Bio is honored to play a part in several pioneering advances of our customers and collaborators ranging from novel infectious disease vaccines, precision immunotherapy for cancer and antibody therapeutics to creation of engineered meat substitutes and sustainable cellular agricultural products.

Therini Bio, Inc. is a biotechnology company dedicated to the research and development of novel therapeutics for the treatment of neuroinflammatory diseases due to vascular dysfunction. Our approach will be generally applicable across a range of inflammatory diseases including peripheral indications. The current therapeutic target is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation.

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of transformational therapies for high unmet medical needs. Timberlyne’s lead program is CM313, an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity that targets CD38. By targeting CD38, which is highly expressed on plasma cells, NK cells, and other immune cells, CM313 modulates multiple immune cell types leading to both rapid and durable responses across a range of autoimmune diseases and cancers.

Tizona Therapeutics, Inc., is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Founded by MPM Capital and leading scientists from Dana Farber Cancer Institute, the University of Pittsburgh, Johns Hopkins, Memorial Sloan Kettering Cancer Center, and Brigham and Women’s Hospital, Tizona’s therapies are designed to modulate the activity of immunosuppressive cells, thereby activating the body’s ability to fight cancer or preventing the immune system from attacking healthy tissues in autoimmune diseases. Our programs target the cell types and biological mechanisms responsible for immune suppression in the tumor microenvironment and for controlling self-reactivity in autoimmunity.

TORL BioTherapeutics is a clinical-stage biopharmaceutical business focused on creating innovative, antibody-based medicines to improve the lives of cancer patients. They are developing a comprehensive pipeline of innovative preclinical ADCs and mAb in oncologic diseases with high unmet medical needs.

Tradewind is dedicated to creating therapeutics for the most aggressive, difficult to treat cancers. Our lead program is a high-affinity, multifaceted attack antibody for cancer that functions through the inhibition of a novel, but validated, target protein. Tradewind’s first-in-class lead program operates through multiple modes of action - directly on cancer cells, and through the immune system, with both mechanisms of attack substantiated by in vivo studies. We can target the primary cancer, metastatic tumors, and even stop metastasis from spreading further. Our mission is to develop only transformative medicines that will have a significant impact on patient outcomes. Tradewind’s drug development is paired with a focus on biomarker identification, ensuring that our therapeutics will benefit the patients for whom it is most meaningful. The lead program is expected to be a game-changer for ovarian cancer, followed by other indications. Tradewind is backed by Y Combinator and the National Cancer Institute (NCI) to advance its innovative approach to fighting cancer.

Trellis Bioscience is a clinical-stage company focused on discovering and developing native human monoclonal antibodies to treat and prevent drug-resistant, life-threatening infectious diseases. Antibodies are the immune system's most potent natural weapon against disease. Trellis's innovative proprietary technology CellSpot™ overcomes technical obstacles that have long hindered exploiting the full human antibody repertoire. This ideal source of drugs focuses on the selection of elite antibodies that bind highly conserved target epitopes with high affinity. TRL1068 is a native human monoclonal antibody (for intravenous delivery) whose target is a family of bacterial proteins (DNABII) that play a critical role in maintaining the structural integrity of biofilms by anchoring extracellular bacterial DNA (eDNA) from dead bacteria within the biofilm matrix. TRL1068 binds at high affinity (Kd ~50 pM) to a highly conserved epitope found in nearly all medically significant bacteria, including both Gram-positive and Gram-negative species. High affinity binding to DNABII ensures that the protein is eliminated from the body and thus prevents its deposition elsewhere in the body, where it could form biofilm metastases. Because the bacterial target is only exposed to the antibody after the producing bacterial cell is dead, resistance to this novel intervention is expected to be rare. The FDA granted Fast Track, QIDP (qualified infectious disease product), and Orphan Drug designations for TRL1068.

We are a cancer therapeutics company with a mission to improve efficacy, reduce toxicity and increase treatment affordability of cancer drugs. We are an experienced team in cancer drug discovery and development. Team members have invented and developed drugs that are approved for cancer treatment. Our approach to eradicating cancer is distinct from the current standard of care. Current approaches involve single agent single action drugs that either inhibit cancer cell growth or inhibit immunosuppression, and hence, they are ineffective. These drugs are combined in a bid to improve efficacy. But combination leads to toxicity, poor efficacy, and high cost. We are developing single agent dual action treatments inhibiting both cancer growth and immunosuppression. We are not targeting the immune checkpoint axis. Our approach will be effective for cancer patients that failed immune checkpoint treatments due to resistance or low expression of PD1, PDL1, CTLA4 etc..

Trishula Therapeutics is a biopharmaceutical company that focuses on developing cancer therapeutics, including the first-in-class anti-CD39 antibody TTX-030.

Founded in 2016, TrueBinding Inc. is a clinical-stage biotherapeutic company researching and developing first-in-class monoclonal antibody drugs to treat Dementia and Alzheimer's Disease (AD).

Twist Bioscience is a synthetic biology company based in South San Francisco, California. The company has developed a proprietary silicon-based manufacturing process for the production of synthetic DNA. Twist Bioscience serves Life Science researchers who are changing the world for the better. Coming from diverse fields of medicine, agriculture, industrial chemicals and data storage, scientists use our synthetic genes, oligo pools, and NGS target enrichment to better lives and improve the sustainability of the planet. Twist Bioscience is uniquely positioned to help accelerate these efforts by providing precision at a scale that is otherwise unavailable. Our technology overcomes inefficiencies and enables cost-effective, rapid, precise, high-throughput DNA synthesis and sequencing. We offer both the quality and quantity researchers need now to rapidly realize opportunities ahead. Twitter @TwistBioscience Facebook facebook.com/TwistBioscience YouTube youtube.com/TwistBioscience #WeMakeDNA

United Immunoassay provides top quality raw materials to the IVD industry.

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company’s lead drug candidate include UBX1325, which is Phase I clinical trial for the treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. It is also developing UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Valora Therapeutics Inc. (Valora) is a pre-clinical stage biopharmaceutical company based in San Diego, California, USA, pioneering a new biologic platform invented by Nobel Laureate Dr. Carolyn Bertozzi (Stanford). Our proprietary platform technology enables the engineering of chimeric antibodies to unlock new mechanisms of immune signaling and activity, paving the way for transformative therapies in oncology, immune diseases, and beyond.

Vascular BioSciences (VBS), a biomedical company with operations in Research Triangle, NC, San Diego, and Goleta, CA, makes interventional catheters to obtain pulmonary endoarterial biopsies, provides molecular diagnostic services, and through its majority-owned subsidiary, VBS Pharmaceuticals, advances targeted therapies in order to enhance and prolong huma

Vector Laboratories empowers scientific advances with innovative proteomic and glycomic solutions. Supporting scientific industries worldwide for 45 years and counting, Vector Laboratories is recognized as a pioneer and market leader in immunofluorescence, immunohistochemistry, and glycobiology products. Scientists in academic, industry, and manufacturing settings continue to rely on Vector Laboratories as a trusted partner in their quest to move science forward, with impact. Our company leadership is steadfast in its mission of empowering scientific curiosity through a culture of service, reliable products, and unmatched technical expertise; a commitment that ultimately allows scientists to make a difference in the world. As an employer, Vector Laboratories instills a work culture focused on the values of integrity, excellence, inclusion, and genuine relationship-building across employees and customers. Vector Laboratories is currently headquartered in Newark, CA. Its rich history in the development of critical and innovative scientific tools and solutions will continue as the organization grows. As the first company to commercialize avidin-biotin enzyme complex kits for immunohistochemistry and antifade mounting media for immunofluorescence, Vector Laboratories has since introduced over 600 reliable reagents and kits. Vector Laboratories products have been cited in more than 350,000 scientific publications and are included in Standard Operating Procedures in labs worldwide. Our genuine commitment to the health, well-being and work-life balance of our employers is reflected in the wide range of benefits we offer. These include competitive compensation, medical, dental, and vision plans, and a generous 401(k) retirement plan. Unique employee perks include • Free use of company condominiums in beautiful Lake Tahoe • Ticket raffle for San Francisco Giants home games (2 tickets)

Vega Therapeutics is a clinical stage biotechnology company developing novel, first-in-class therapies for rare blood disorders with overlooked patient needs, starting with von Willebrand disease (VWD). Our lead product candidate, VGA039, is the first purpose-built antibody therapy for VWD with a novel mechanism of action targeting Protein S. By attenuating Protein S cofactor function for tissue factor pathway inhibitor α (TFPIα) and activated protein C (aPC), VGA039 augments and restores thrombin generation during both initiation and propagation of coagulation, addressing a fundamental mechanism of clot formation in VWD. VGA039 has potential to be a universal hemostatic therapy that can treat various bleeding disorders. Vega is part of a constellation of companies led by Star Therapeutics, a company focused on developing life-changing therapies for people with rare diseases.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Vincerx Pharma Inc. is focused to address the unmet medical needs of our patients with paradigm-shifting therapeutics.

Vir Biotechnology, Inc. (in Europe, Humabs BioMed, https://bit.ly/46lQGN2) is an immunology company focused on powering the immune system to address unmet patient needs in infectious disease and beyond. Our powerful R&D engine combines our proprietary monoclonal antibody (mAb) platform with machine learning and artificial intelligence-enhanced capabilities, enabling us to engineer our rich database of human antibodies and deliver transformative medicines for diseases with significant global burden. Our current pipeline consists of multiple clinical candidates targeting hepatitis B and hepatitis delta viruses and human immunodeficiency virus, including a potential functional cure for chronic hepatitis B and treatment for chronic hepatitis delta. Our portfolio of broad, potent investigational monoclonal antibodies also targets influenza A and B viruses, COVID-19, respiratory syncytial virus/human metapneumovirus and human papillomavirus, and our investigational T cell vaccine aims to prevent HIV. Explore our full pipeline: https://bit.ly/3tr7FPm We collaborate with some of the world’s leaders in industry as well as government agencies and non-profit organizations enabling us to rapidly advance cutting-edge scientific discoveries and innovative technologies with the potential to benefit people around the world. We are proud to have been ranked the fastest-growing company in North America on the 2022 Deloitte Technology Fast 500™. Join us as we pursue our mission to transform lives. It has come to our attention that there have been various recruitment scams targeting job seekers on LinkedIn. Vir Biotechnology, Inc. is committed to your privacy and will never request sensitive personal information including banking details through email, text message, social media or video software platforms. We also will never request a financial commitment from a candidate as part of the application process. Learn more about Vir’s recruiting process: https://bit.ly/461EgJN

Vironexis is focused on transforming the future of cancer treatment by pioneering AAV-delivered T-cell immunotherapy. Our TransJoin™ AAV Gene Therapy Platform enables the creation of off-the-shelf, single-dose gene therapies designed to overcome the key challenges and shortcomings of current immunotherapies, including CAR-T and bispecific antibodies. Our current pipeline includes more than ten product candidates for blood-based cancers, solid tumor metastasis prevention, and a cancer vaccine. Our lead program, VNX-101, for the treatment of CD19+ acute lymphoblastic leukemia, is anticipated to begin clinical trials in the fourth quarter of 2024.

Virtuoso Therapeutics is an oncology-focused company developing novel bispecific antibody therapies. Our team’s expertise and insights could address some of the fundamental challenges of these modalities, such as efficacy and therapeutic window. By applying Virtuoso’s technology and know-how, we believe our bispecific programs are highly differentiated and have the potential to achieve a unique product profile. Virtuoso leadership has extensive experience and networks across both the US and China. Our unique US-China hybrid model enables capital-efficient virtual R&D operations, as well as access to world-class science and talent from China and the West.

Vivace Therapeutics is a venture-backed, oncology-focused portfolio-based drug discovery and development company, based in San Mateo, California. Its programs include both small molecule programs targeting the YAP pathway, and bi-specific programs. For more information on the company, please visit the company website www.vivacetherapeutics.com. The company's scientific founders are Dr. Kun-liang Guan of UCSD, Dr. Bin Liu of UCSF and Dr. Sheng Ding of UCSF.

VST-Bio’s team envisions a future where ischemic stroke and myocardial infraction no longer impose a life-threatening tissue damage or progression to neurological dysfunction or heart failure.

Vybion developed a novel vectorized intrabody (INT41) for Huntington’s disease, a devastating inherited orphan disease that results in the progressive loss of both motor and cognitive function. INT41 is effective in both cell-based system and animal models. INT41 has Orphan Disease Designation from the FDA and a pre-IND meeting defined the basic elements of the IND enabling package. INT41 binds to an epitope that is unavailable in the functional molecule, but appears in the toxic degradation fragment that accumulates in the nucleus, binds to DNA via the polyglutamine and alters gene expression detectable years before the onset of symptoms. INT41 stabilizes this fragment and facilitates its degradation. In addition to Huntington’s disease, Vybion is testing INT41 as a therapy for spinobulbar muscular atrophy (SBMA) and spinocerebellar Ataxia 1, 3 and 7 (SCA), two closely related Orphan diseases with an identical target sequence and polyglutamine expansion as seen in Huntington’s disease.

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases. It develops its antibody product candidates to treat cancer and autoimmune diseases. The company’s product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; AIMab7195, which is in development and commercialization stage. Its product candidates also comprise XmAb14045, a bispecific antibody which is in Phase I clinical trial for the treatment of acute myeloid leukemia; plamotamab (XmAb13676) that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers Tafasitamab, an antibody drug candidate for the treatment of patients with relapsed/refractory diffuse; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG509, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104 which are in preclinical Phase. Additionally, it offers XmAb24306, initial cytokine candidate which is in Phase I clinical trial. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; Amgen Inc.; Catalent Pharma Solutions LLC.; Janssen Biotech, Inc.; MorphoSys AG; Incyte Corporation; and The University of Texas MD Anderson Cancer Center. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.

XOMA Royalty Corporation is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of royalty and milestone assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com. All references to “portfolio” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates in XOMA’s posts strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.

Y-Trap, Inc., is a biotechnology company focused on the development of revolutionary technologies for cancer immunotherapy. The company's patented technology is a novel platform of targeted multifunctional immunomodulatory antibody-ligand traps for cancer immunotherapy. The ability of this novel class of next-generation multifunctional antibody-ligand traps to unleash potent antitumor immune responses offers a promising targeted immunotherapeutic strategy for many types of advanced and treatment-refractory cancers that evade current monoclonal antibodies and immune checkpoint inhibitors.

ZabBio is a biopharmaceutical company that focuses on developing monoclonal antibody-based products to address unmet needs in infectious diseases and reproductive health, with a focus on large, cost-sensitive markets.

Zafrens is a therapeutics company pioneering an ultra-high throughput platform to isolate, culture, image, and sequence millions of cells per day. The proprietary platform allows for full characterization of diverse cell populations, as well as directly correlating molecular profiles (DNA, RNA, protein) to cell phenotype and function. The company’s mission is to unlock the full story of every cell to accelerate drug discovery.

Zai Lab is an innovative, research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for cancer, autoimmune, and infectious diseases to patients in China and around the world. The company was founded by Dr. Samantha Du, Chairperson and CEO, in 2014 to help address significant unmet medical needs in China and to be at the forefront of medical innovation.

Zyagen develops, manufactures, and sells life science products, biochemical, and reagents for cellular localization, expression, and quantitative analysis of genes and their protein products. Zyagenalso offer custom research services in histology and molecular biology for pharmaceutical, biotechnology, federal, and academic research institutes worldwide.